## **NEW YORK STATE**

**MEDICAID PROGRAM** 

**NURSE PRACTITIONER** 

**PROCEDURE CODES** 

## **Table of Contents**

GENERAL INFORMATION	3
SERVICES PROVIDED IN ARTICLE 28 FACILITIES	5
MMIS MODIFIERS	6
MEDICINE SECTION	8
GENERAL RULES AND INFORMATION	8
EVALUATION AND MANAGEMENT CODES	15
LABORATORY SERVICES PERFORMED IN THE OFFICE	31
DRUGS AND DRUG ADMINISTRATION	32
IMMUNIZATIONS	32
DRUGS ADMINISTERED OTHER THAN ORAL METHOD	37
HYDRATION, THERAPEUTIC, PROPHYLACTIC, DIAGNOSTIC INJECTIONS	45
CHEMOTHERAPY DRUGS	49
PSYCHIATRY	50
SPECIAL OPHTHALMOLOGICAL SERVICES	51
CARDIOVASCULAR	52
PULMONARY	53
ALLERGY AND CLINICAL IMMUNOLOGY	53
MISCELLANEOUS SERVICES	53
SURGERY SECTION	54
GENERAL INFORMATION AND RULES	55
INTEGUMENTARY SYSTEM	56
DIGESTIVE SYSTEM	57
FEMALE GENITAL SYSTEM	58
MATERNITY CARE	58
NERVOUS SYSTEM	59
AUDITORY SYSTEM	59

## **GENERAL INFORMATION**

- 1. **MULTIPLE CALLS**: If an individual patient is seen on more than one occasion during a single day, the fee for each visit may be allowed.
- CHARGES FOR DIAGNOSTIC PROCEDURES: Charges for special diagnostic procedures which
  are not considered to be a routine part of an examination (eg, ECG) are reimbursable in addition
  to the usual visit fee.
- 3. **SEPARATE PROCEDURE**: Certain of the listed procedures are commonly carried out as an integral part of a total service and as such do not warrant a separate charge. When such a procedure is carried out as a <u>separate entity</u>, not immediately related to other services, the indicated value for "Separate Procedure" is applicable.
- 4. REFERRAL: A referral is the transfer of the total or specific care of a patient from one physician or nurse practitioner to another and does not constitute a consultation. Initial evaluation and subsequent services are designated as listed in LEVELS OF E/M SERVICE. Referral is to be distinguished from consultation. REFERRAL is the transfer of the patient from one practitioner to another for definitive treatment.
- CONSULTATION: is advice and opinion from an accredited physician specialist called in by the attending practitioner in regard to the further management of the patient by the attending practitioner.

Consultation fees are applicable only when examinations are provided by an accredited physician specialist within the scope of his specialty upon request of the authorizing agency or of the attending practitioner who is treating the medical problem for which consultation is required. The attending practitioner must certify that he requested such consultation and that it was incident and necessary to his further care of the patient.

When the consultant physician assumes responsibility for a portion of patient management, he will be rendering concurrent care (use appropriate level of evaluation and management codes). If he has had the case transferred or referred to him, he should then use the appropriate codes for services rendered (eg, visits, procedures) on and subsequent to the date of transfer.

6. **BY REPORT**: A service that is rarely provided, unusual, variable, or new may require a special report in determining medical appropriateness of the service. Pertinent information should include an adequate definition or description of the nature, extent, and need for the procedure, and the time, effort and equipment necessary to provide the service. Additional items which may be included are: Complexity of symptoms, final diagnosis, pertinent physical findings (such as size, locations, and number of lesions(s), if appropriate), diagnostic and therapeutic procedures (including major and supplementary surgical procedures, if appropriate), concurrent problems, and follow-up care.

When the value of a procedure is to be determined "By Report" (BR), information concerning the nature, extent and need for the procedure or service must be furnished in addition to the time, skill

Version 2017 Page 3 of 59

#### **Nurse Practitioner Procedure Codes**

and equipment necessitated. Appropriate documentation (eg, procedure description, itemized invoices, etc.) should accompany all claims submitted.

Itemized invoices must document acquisition cost, the line item cost from a manufacturer or wholesaler net of any rebates, discounts or other valuable considerations.

7. MATERIALS SUPPLIED BY PRACTITIONER: Supplies and materials provided, eg, sterile trays/drugs, over and above those usually included with the procedure(s), office visit or other services rendered may be listed separately. List drugs, trays, supplies and materials provided. Identify as 99070 or specific supply code.

Reimbursement for supplies and material (including drugs, vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner. For all items furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the item provided.

- 8. **PRESCRIBER WORKSHEET**: Enteral formula requires voice interactive telephone prior authorization from the Medicaid program. The prescriber must initiate the authorization through this system. The worksheet specifies the questions asked on the voice interactive telephone system and must be maintained in the patient's clinical record. The worksheet can be found on the Provider Communication link. <a href="MedNY">eMedNY</a> : Provider Manuals : Nurse Practitioner Provider Communications
- PRIOR APPROVAL: Payment for those listed procedures where the MMIS code number is underlined is dependent upon obtaining the approval of the Department of Health prior to performance of the procedure. If such prior approval is not obtained, no reimbursement will be made.

Version 2017 Page 4 of 59

**RADIOLOGY PRIOR APPROVAL**: Information for Ordering Providers- If you are **ordering** a CT, CTA, MRI, MRA, Cardiac Nuclear, or PET procedure, you or your office staff are required to obtain an approval number through the RadConsult program. Requests will be reviewed against guidelines, and a prior approval number will be issued.

Using a secure login, you will have the ability to access RadConsult Online or call the RadConsult contact center to check the status of procedure requests.

Beneficiaries who are eligible for both Medicaid and Medicare (dual eligible) or beneficiaries who are enrolled in a managed care plan are not included.

Additional information is available at <a href="http://www.emedny.org/ProviderManuals/Radiology/index.html">http://www.emedny.org/ProviderManuals/Radiology/index.html</a>

- 10. **DVS AUTHORIZATION (#)**: Codes followed by **#** require an authorization via the dispensing validation system (DVS) before services are rendered.
- 11. PAYMENT IN FULL: Fees paid in accordance with the allowances in the Medical Fee Schedule shall be considered full payment for services rendered. No additional charge shall be made by a practitioner.
- 12. **FEES**: The fees are listed in the Nurse Practitioner Fee Schedule, available at <a href="http://www.emedny.org/ProviderManuals/NursePractitioner/index.html">http://www.emedny.org/ProviderManuals/NursePractitioner/index.html</a>

Listed fees are the maximum reimbursable Medicaid fees. Fees for the MOMS Program and PPAC Program can be found in the Enhanced Program Fee Schedule.

## SERVICES PROVIDED IN ARTICLE 28 FACILITIES

The professional component for all services provided by a nurse practitioner in an Article 28 hospital outpatient clinic, hospital inpatient setting, emergency department, ambulatory surgery setting and diagnostic and treatment center (D&TC) for Medicaid fee-for-service patients is included in the APG or APR-DRG payment to the facility. Nurse practitioners may not bill Medicaid separately for professional services provided in an Article 28 facility.

Version 2017 Page 5 of 59

## **MMIS MODIFIERS**

Note: NCCI associated modifiers are recognized for NCCI code pairs/related edits. For additional information please refer to the CMS website:

http://www.cms.hhs.gov/NationalCorrectCodInitEd/

Under certain circumstances, the MMIS code identifying a specific procedure or service must be expanded by two additional characters to further define or explain the nature of the procedure.

The circumstances under which such further description is required are detailed below along with the appropriate modifiers to be added to the basic code when the particular circumstance applies.

- -24 <u>Unrelated Evaluation and Management Service by the Same Practitioner during a Postoperative Period</u>: The practitioner may need to indicate that an evaluation and management service was performed during a postoperative period for a reason(s) unrelated to the original procedure. This circumstance may be reported by adding the modifier -24 to the appropriate level of E/M service. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- Significant, Separately Identifiable Evaluation and Management Service by the Same Practitioner on the Day of a Procedure: (Effective 10/1/92) The practitioner may need to indicate that on the day a procedure or service identified by an MMIS code was performed, the patient's condition required a significant, separately identifiable E/M service above and beyond the usual preoperative and postoperative care associated with the procedure that was performed. The E/M service may be prompted by the symptom or condition, for which the procedure and/or service was provided. As such, different diagnoses are not required for reporting of the E/M services on the same date. This circumstance may be reported by adding the modifier -25 to the appropriate level of E/M service.

**NOTE**: This modifier is not used to report an E/M service that resulted in a decision to perform surgery. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)

- -77 Repeat Procedure by Another Practitioner: The practitioner may need to indicate that a basic procedure performed by another practitioner had to be repeated. This situation may be reported by adding modifier -77 to the repeated service. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -79 <u>Unrelated Procedure or Service by the Same Practitioner During the Postoperative Period</u>: The practitioner may need to indicate that the performance of a procedure or service during the postoperative period was unrelated to the original procedure. This circumstance may be reported by using the modifier -79 to the related procedure. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -EP <u>Child/Teen Health Program (EPSDT Program)</u>: Service provided as part of the Medicaid Early Periodic Screening, Diagnosis and Treatment (EPSDT) Program or Child/Teen Health Program will be identified by adding the modifier -EP to the usual procedure number. (Reimbursement will not exceed 100% of the maximum State Medical Fee Schedule amount.)
- -FP <u>Service Provided as Part of Family Planning Program</u>: All Family Planning Services will be identified by adding the modifier '-FP' to the usual procedure code: number. (Reimbursement will not exceed 100% of the maximum State' Medical Fee Schedule amount.)

Version 2017 Page 6 of 59

#### **Nurse Practitioner Procedure Codes**

-SL <u>State Supplied Vaccine</u>: (Used to identify administration of vaccine supplied by the Vaccines for Children Program (VFC) for children under 19 years of age). When administering vaccine supplied by the state (VFC program), you **must** append modifier –SL State Supplied Vaccine to the procedure code number representing the vaccine administered. Omission of this modifier on claims for recipients under 19 years of age will cause your claim to deny. (Reimbursement will not exceed \$17.85, the administration fee for the VFC program.)

Version 2017 Page 7 of 59

## **MEDICINE SECTION**

#### GENERAL RULES AND INFORMATION

- 1. PRIMARY CARE: Primary care is first contact care, the type furnished to individuals when they enter the health care system. Primary care is comprehensive in that it deals with a wide range of health problems, diagnosis and modes of treatment. Primary care is continuous in that an ongoing relationship is established with the primary care practitioner who monitors and provides the necessary follow-up care and is coordinated by linking patients with more varied specialized services when needed. Consultations and care provided on referral from another practitioner is not considered primary care.
- 2. CLASSIFICATION OF EVALUATION AND MANAGEMENT (E/M) SERVICES: The Federal Health Care Finance Administration has mandated that all state Medicaid programs utilize the new Evaluation and Management coding as published in the American Medical Association's CPT.

For the first time, a major section has been devoted entirely to E/M services. The new codes are more than a clarification of the old definitions; they represent a new way of classifying the work of practitioners. In particular, they involve far more clinical detail than the old visit codes. For this reason, it is important to treat the new codes as a new system and not make a one-for-one substitution of a new code number for a code number previously used to report a level of service defined as "brief", "limited", "intermediate", etc.

The E/M section is divided into broad categories such as office visits, hospital visits and consultations. Most of the categories are further divided into two or more subcategories of E/M services. For example, there are two subcategories of office visits (new patient and established patient) and there are two subcategories of hospital visits (initial and subsequent). The subcategories of E/M services are further classified into levels of E/M services that are identified by specific codes. This classification is important because the nature of practitioner work varies by type of service, place of service, and the patient's status.

The basic format of the levels of E/M services is the same for most categories. First, a unique code number is listed. Second, the place and/or type of service is specified, eg, office consultation. Third, the content of the service is defined, eg, comprehensive history and comprehensive examination. (See levels of E/M services following for details on the content of E/M services.) Fourth, the nature of the presenting problem(s) usually associated with a given level is described. Fifth, the time typically required to provide the service is specified.

3. **DEFINITIONS OF COMMONLY USED E/M TERMS**: Certain key words and phrases are used throughout the E/M section. The following definitions are intended to reduce the potential for differing interpretations and to increase the consistency of reporting.

<u>NEW AND ESTABLISHED PATIENT</u>: A new patient is one who has not received any professional services from the practitioner or practitioners working in the same specialty within the same group within the past three years.

An established patient is one who has received professional services from the practitioner within the past three years.

Version 2017 Page 8 of 59

In the instance where a practitioner is on call for or covering for another practitioner, the patient's encounter will be classified as it would have been by the practitioner who is not available.

No distinction is made between new and established patients in the emergency department. E/M services in the emergency department category may be reported for any new or established patient who presents for treatment in the emergency department.

<u>CHIEF COMPLAINT</u>: A concise statement describing the symptom, problem, condition, diagnosis or other factor that is the reason for the encounter, usually stated in the patient's words.

<u>CONCURRENT CARE</u>: is the provision of similar services, eg, hospital visits, to the same patient by more than one practitioner on the same day. When concurrent care is provided, no special reporting is required. Modifier -75 has been deleted.

<u>COUNSELING</u>: Counseling is a discussion with a patient and/or family concerning one or more of the following areas:

- diagnostic results, impressions, and/or recommended diagnostic studies;
- prognosis;
- risks and benefits of management (treatment) options;
- instructions for management (treatment) and/or follow-up;
- importance of compliance with chosen management (treatment)options;
- risk factor reduction; and
- patient and family education.

<u>FAMILY HISTORY</u>: A review of medical events in the patient's family that includes significant information about:

- the health status or cause of death of parents, siblings, and children;
- specific diseases related to problems identified in the Chief Complaint or History of the Present Illness, and/or System Review;
- diseases of family members which may be hereditary or place the patient at risk.

<u>HISTORY OF PRESENT ILLNESS</u>: A chronological description of the development of the patient's present illness from the first sign and/or symptom to the present. This includes a description of location, quality, severity, timing, context, modifying factors and associated signs and symptoms significantly related to the presenting problem(s).

<u>NATURE OF PRESENTING PROBLEM</u>: A presenting problem is a disease, condition, illness, injury, symptom, sign, finding, complaint, or other reason for encounter, with or without a diagnosis being established at the time of the encounter. The E/M codes recognize five types of presenting problems that are defined as follows:

- Minimal A problem that may not require the presence of the practitioner, but service is provided under the practitioner's supervision.
- Self-limited or Minor A problem that runs a definite and prescribed course, is transient in nature and is not likely to permanently alter health status OR has a good prognosis with management/compliance.
- Low severity A problem where the risk of morbidity without treatment is low; there is little
  to no risk of mortality without treatment; full recovery without functional impairment is
  expected.

Version 2017 Page 9 of 59

- Moderate severity A problem where the risk of morbidity without treatment is moderate; there is moderate risk of mortality without treatment; uncertain prognosis OR increased probability of prolonged functional impairment.
- High severity A problem where the risk of morbidity without treatment is high to extreme; there is a moderate to high risk of mortality without treatment OR high probability of severe, prolonged functional impairment.

<u>PAST HISTORY</u>: A review of the patient's past experiences with illnesses, injuries, and treatments that includes significant information about:

- · prior major illnesses and injuries;
- prior operations;
- prior hospitalizations;
- current medications;
- allergies (e.g., drug, food);
- age appropriate immunization status;
- age appropriate feeding/dietary status.

<u>SOCIAL HISTORY</u>: an age appropriate review of past and current activities that include significant information about:

- marital status and/or living arrangements;
- current employment;
- occupational history;
- use of drugs, alcohol, and tobacco;
- level of education;
- sexual history:
- other relevant social factors.

<u>SYSTEM REVIEW (REVIEW OF SYSTEMS)</u>: An inventory of body systems obtained through a series of questions seeking to identify signs and/or symptoms which the patient may be experiencing or has experienced. The following elements of a system review have been identified:

- Constitutional symptoms (fever, weight loss, etc.)
- Eyes
- Ears, Nose, Mouth, Throat
- Cardiovascular
- Respiratory
- Gastrointestinal
- Genitourinary
- Musculoskeletal
- Integumentary (skin and/or breast)
- Neurological
- Psychiatric
- Endocrine
- Hematologic/Lymphatic
- Allergic/Immunologic

Version 2017 Page 10 of 59

The review of systems helps define the problem, clarify the differential diagnoses, identify needed testing, or serves as baseline data on other systems that might be affected by any possible management options.

<u>TIME</u>: The inclusion of time in the definitions of levels of E/M services has been implicit in prior editions. The inclusion of time as an explicit factor beginning in 1992 is done to assist practitioners in selecting the most appropriate level of E/M services. It should be recognized that the specific times expressed in the visit code descriptors are averages, and therefore represent a range of times which may be higher or lower depending on actual clinical circumstances.

Time is **not** a descriptive component for the emergency department levels of E/M services because emergency department services are typically provided on a variable intensity basis, often involving multiple encounters with several patients over an extended period of time. Therefore, it is often difficult for practitioners to provide accurate estimates of the time spent faceto-face with the patient.

Intra-service times are defined as **face-to-face** time for office and other outpatient visits and as unit/floor time for hospital or other inpatient visits. This distinction is necessary because most of the work of typical office visits takes place during the face-to-face time with the patient, while most of the work of typical hospital visits takes place during the time spent on the patient's floor or unit.

A. Face-to-face time (e.g., office and other outpatient visits, office consultations and all psychiatry procedures): For coding purposes, face-to-face time for these services is defined as only that time the practitioner spends face-to-face with the patient and/or family. This includes the time in which the practitioner performs such tasks as obtaining a history, performing an examination, and counseling the patient.

Practitioners also spend time doing work before or after face-to-face time with the patient, performing such tasks reviewing records and tests, arranging for further services, and communicating further with other professionals and the patient through written reports and telephone contact.

This non face-to-face time for office services – also called pre- and post-encounter time – is not included in the time component described in the E/M codes. However, the pre- and post-face-to-face work associated with an encounter was included in calculating the total work of typical services.

Thus, the face-to-face time associated with the services described by any E/M code is a valid proxy for the total work done before, during, and after the visit.

B. **Unit/floor time (inpatient hospital care)**: For reporting purposes, intra-service time for these services is defined as unit/floor time, which includes the time that the practitioner is present on the patient's hospital unit and at the bedside rendering services for that patient. This includes the time in which the practitioner establishes and/or reviews the patient's

Version 2017 Page 11 of 59

chart, examines the patient, writes notes and communicates with other professionals and the patient's family.

In the hospital, pre- and post-time includes time spent off the patient's floor performing such tasks as reviewing pathology and radiology findings in another part of the hospital. This pre- and post-visit time is not included in the time component described in these codes. However, the pre- and post-work performed during the time spent off the floor or unit was included in calculating the total work of typical services.

Thus, the unit/floor time associated with the services described by any code is a valid proxy for the total work done before, during and after the visit.

4A. **LEVELS OF E/M SERVICES**: Within each category or subcategory of E/M service, there are three to five levels of E/M services available for reporting purposes. Levels of E/M services are not interchangeable among the different categories or subcategories of service. For example, the first level of E/M services in the subcategory of office visit, new patient, does not have the same definition as the first level of E/M services in the subcategory of office visit, established patient.

The levels of E/M services include examinations, evaluations, treatments, conferences with or concerning patients, preventive health supervision, and similar medical services such as the determination of the need and/or location for appropriate care. Medical screening includes the history, examination, and medical decision-making required to determine the need and/or location for appropriate care and treatment of the patient (e.g., office and other outpatient setting, emergency department, nursing facility, etc.). The levels of E/M services encompass the wide variations in skill, effort, time, responsibility and medical knowledge required for the prevention or diagnosis and treatment of illness or injury and the promotion of optimal health.

The descriptors for the levels of E/M services recognize seven components, six of which are used in defining the levels of E/M services. These components are: history; examination, medical decision making, counseling; coordination of care; nature of presenting problem, and time.

The first three of these components (history, examination and medical decision making) are considered the key components in selecting a level of E/M services.

The next three components (counseling, coordination of care, and the nature of the presenting problem) are considered contributory factors in the majority of encounters. Although the first two of these contributory factors are important E/M services, it is not required that these services be provided at every patient encounter. The final component, time, has already been discussed in detail.

The actual performance of diagnostic tests/studies for which specific codes are available is not included in the levels of E/M services. Practitioner performance of diagnostic tests/studies for which specific codes are available should be reported separately, in addition to the appropriate E/M code.

Version 2017 Page 12 of 59

#### 4B. INSTRUCTIONS FOR SELECTING A LEVEL OF E/M SERVICE:

- i. <u>IDENTIFY THE CATEGORY AND SUBCATEGORY OF SERVIC</u>E: Select from the categories and subcategories of codes available for reporting E/M services.
- ii. REVIEW THE REPORTING INSTRUCTIONS FOR THE SELECTED CATEGORY OR SUBCATEGORY: Most of the categories and many of the subcategories of service have special guidelines or instructions unique to that category or subcategory. Where these are indicated, e.g., "Hospital Care", special instructions will be presented preceding the levels of E/M services.
- iii. REVIEW THE LEVEL OF E/M SERVICE DESCRIPTORS AND EXAMPLES IN THE SELECTED CATEGORY OR SUBCATEGORY: The descriptors for the levels of E/M services recognize seven components, six of which are used in defining the levels of E/M services. These components are: history, examination, medical decision making, counseling, coordination of care, nature of presenting problem, and time.

The first three of these components (i.e., history, examination and medical decision making) should be considered the key components in selecting the level of E/M services. An exception to this rule is in the case of visits which consist predominantly of counseling or coordination of care (see vii.c.).

The nature of the presenting problem and time are provided in some levels to assist the practitioner in determining the appropriate level of E/M service.

- iv. <u>DETERMINE THE EXTENT OF HISTORY OBTAINED</u>: The levels of E/M services recognize four types of history that are defined as follows:
  - Problem Focused chief complaint, brief history of present illness or problem.
  - Expanded Problem Focused chief complaint; brief history of present illness; problem pertinent system review.
  - Detailed chief complaint; extended history of present illness; problem pertinent system
    review extended to include review of a limited number of additional systems; pertinent
    past, family and/or social history directly related to the patient's problems.
  - Comprehensive chief complaint; extended history of present illness; review of systems which is directly related to the problem(s) identified in the history of the present illness plus a review of all additional body systems; complete past, family and social history.

The comprehensive history obtained as part of the preventive medicine evaluation and management service is not problem-oriented and does not involve a chief complaint of present illness. It does, however, include a comprehensive system review and comprehensive or interval past, family and social history as well as a comprehensive assessment/history of pertinent risk factors.

- v. <u>DETERMINE THE EXTENT OF EXAMINATION PERFORMED</u>: The levels of E/M services recognize four types of examination that are defined as follows:
  - Problem Focused a limited examination of the affected body area or organ system.
  - Expanded Problem Focused a limited examination of the affected body area or organ system and other symptomatic or related organ system(s).
  - Detailed an extended examination of the affected body area(s) and other symptomatic or related organ system(s).

Version 2017 Page 13 of 59

 Comprehensive – a general multi-system examination or a complete examination of a single organ system. NOTE: The comprehensive examination performed as part of the preventive medicine evaluation and management service is multi-system, but its extent is based on age and risk factors identified.

For the purposes of these definitions, the following organ systems are recognized: eyes, ears, nose, mouth and throat; cardiovascular; respiratory; gastrointestinal; genitourinary; musculoskeletal; skin, neurologic; psychiatric; hematologic/lymphatic/immunologic.

- vi. <u>DETERMINE THE COMPLEXITY OF MEDICAL DECISION MAKING</u>: Medical decision making refers to the complexity of establishing a diagnosis and/or selecting a management option as measured by:
  - the number of possible diagnoses and/or the number of management options that must be considered;
  - the amount and/or complexity of medical records, diagnostic tests, and/or other information that must be obtained, reviewed and analyzed; and
  - the risk of significant complications, morbidity and/or mortality, as well as co-morbidities, associated with the patient's presenting problem(s), the diagnostic procedure(s) and/or the possible management options.

Four types of medical decision making are recognized: straightforward; low complexity; moderate complexity, and, high complexity. To qualify for a given type of decision making, two of the three elements in the table following must be met or exceeded:

Number of diagnoses or	Amount and/or	Risk of complications	Type of decision
management options	complexity of data	and/or morbidity or	making
	to be reviewed	mortality	
minimal	minimal or none	minimal	straightforward
limited	limited	low	low complexity
multiple	moderate	moderate	moderate complexity
extensive	extensive	high	high complexity

Co-morbidities/underlying disease, in and of themselves, are not considered in selecting a level of E/M services unless their presence significantly increases the complexity of the medical decision making.

## vii. SELECT THE APPROPRIATE LEVEL OF E/M SERVICES BASED ON THE FOLLOWING:

- a. For the following categories/subcategories, ALL OF THE KEY COMPONENTS (ie, history, examination, and medical decision making), must meet or exceed the stated requirements to qualify for a particular level of E/M service: office, new patient; hospital observation services; initial hospital care; office consultations; initial): inpatient consultations, emergency department services; initial nursing facility care; domiciliary care, new patient; and home, new patient.
- b. For the following categories/subcategories, TWO OF THE THREE KEY COMPONENTS (i.e., history, examination, and medical decision making) must meet or exceed the stated requirements to qualify for a particular level of E/M services: office, established patient; subsequent hospital care; subsequent nursing facility care; domiciliary care, established patient; and home, established patient.
- c. In the case where counseling and or coordination of care dominates (more than 50%) the practitioner/patient and/or family encounter (face-to-face time in the office or other

Version 2017 Page 14 of 59

outpatient setting or floor/unit time in the hospital), then **time** is considered the key or controlling factor to qualify for a particular level of E/M services. The extent of counseling and/or coordination of care must be documented in the medical record.

<u>NOTE: CLINICAL EXAMPLES</u>: Clinical examples of the codes for E/M services are provided to assist practitioners in understanding the meaning of the descriptors and selecting the correct code.

The same problem, when seen by physicians in different specialties, may involve different amounts of work. Therefore, the appropriate level of encounter should be reported using the descriptor rather than the examples.

 FAMILY PLANNING CARE: In accordance with approval received by the State Director of the Budget, effective July 1, 1973 in the Medicaid Program, all family planning services are to be reported on claims using appropriate MMIS code numbers listed in this fee schedule in combination with modifier -FP.

This reporting procedure will assure to New York State the higher level of federal reimbursement which is available when family planning services are provided to Medicaid patients (90% instead of 50% for other medical care). It will also provide the means to document conformity with mandated federal requirements on provision of family planning services.

6. **EVALUATION AND MANAGEMENT SERVICES (OUTPATIENT OR INPATIENT)**: Evaluation and management fees do not apply to preoperative consultations or follow-up visits as designated in accordance with the surgical fees listed in the SURGERY section of the State Medical Fee Schedule.

For additional information on the appropriate circumstances governing the billing of the hospital visit procedure codes see **PRACTITIONER SERVICES PROVIDED IN HOSPITALS**.

## **EVALUATION AND MANAGEMENT CODES**

Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs.

## OFFICE OR OTHER OUTPATIENT SERVICES

The following codes are used to report evaluation and management services provided in the practitioner's office or in an outpatient or other ambulatory facility. A patient is considered an outpatient until inpatient admission to a health care facility occurs. When claiming for Evaluation and Management procedure codes report the place of service code that represents the location where the service was rendered in the claim form field for Place of Service. The maximum reimbursable amount for these codes is dependent on the Place of Service reported.

For Evaluation and Management services rendered in the practitioner's private office, report place of service "11". For services rendered in a Hospital Outpatient setting report place of service "22".

Version 2017 Page 15 of 59

To report services provided to a patient who is admitted to a hospital or nursing facility in the course of an encounter in the office or other ambulatory facility, see the notes for initial hospital inpatient care or comprehensive nursing facility assessments.

#### **NEW PATIENT**

99201 Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components:

- a problem focused history,
- a problem focused examination, and
- straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor. Practitioners typically spend 10 minutes face-to-face with the patient and/or family.

99202 Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- straightforward medical decision making.

Usually, the presenting problem(s) are of low to moderate severity. Practitioners typically spend 20 minutes face-to-face with the patient and/or family.

99203 Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components:

- a detailed history,
- a detailed examination, and
- medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes face-to-face with the patient and/or family.

99204 Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 45 minutes face-to-face with the patient and/or family.

99205 Office or other outpatient visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- · a comprehensive examination, and
- medical decision making of high complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 60 minutes face-to-face with the patient and/or family.

#### **ESTABLISHED PATIENT**

Version 2017 Page 16 of 59

The following codes are used to report the evaluation and management services provided to established patients who present for follow-up and/or periodic reevaluation of problems or for the evaluation and management of new problem(s) in established patients.

99211 Office or other outpatient visit for the evaluation and management of an established patient that may not require the presence of a practitioner.

Usually, the presenting problem(s) are minimal. Typically, 5 minutes are spent performing or supervising these services.

99212 Office or other outpatient visit for the evaluation and two of these three key components:

- a problem focused history,
- a problem focused examination, and/or
- · straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor. Practitioners typically spend 10 minutes face-to-face with the patient and/or family.

99213 Office or other outpatient visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and/or
- medical decision making of low complexity.

Usually, the presenting problem(s) are of low to moderate severity. Practitioners typically spend 15 minutes face-to-face with the patient and/or family.

99214 Office or other outpatient visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a detailed history,
- a detailed examination, and/or
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 25 minutes face-to-face with the patient and/or family.

99215 Office or other outpatient visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a comprehensive history,
- a comprehensive examination, and/or
- medical decision making of high complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes face-to-face with the patient and/or family.

## **HOSPITAL OBSERVATION SERVICES**

The following codes are used to report evaluation and management services provided to patients designated/admitted as "observation status" in a hospital. It is not necessary that the patient be located in an observation are designated by the hospital. If such an area does exist in a hospital (as a

Version 2017 Page 17 of 59

separate unit in the hospital, in the emergency department, etc.), these codes are to be utilized if the patient is placed in such an area.

Typical times have not yet been established for this category of services.

#### OBSERVATION CARE DISCHARGE SERVICES

Observation care discharge of a patient from "observation status" includes final examination of the patient, discussion of the hospital stay, instructions for continuing care, and preparation of discharge records. For observation or inpatient hospital care including the admission and discharge of the patient on the same date, see codes 99234-99236 as appropriate.

99217 Observation care discharge day management (This code is to be utilized by the practitioner to report all services provided to a patient on discharge from "observation status" if the discharge is on other that the initial date of "observation status". To report services to a patient designated as "observation status" or "inpatient status" and discharged on the same date, use the codes for Observation or Inpatient Care Services (99234-99236).

## INITIAL OBSERVATION CARE- NEW OR ESTABLISHED PATIENT

The following codes are used to report the encounter(s) by the supervising practitioner with the patient when designated as "observation status". This refers to the initiation of observation status, supervision of the care plan for observation and performance of periodic reassessments.

To report services provided to a patient who is admitted to the hospital after receiving hospital observation care services on the same date, see the notes for initial hospital inpatient care. For a patient admitted to the hospital on a date subsequent to the date of observation status, the hospital admission would be reported with the appropriate initial hospital care codes (99221-99223). For a patient admitted and discharged from observation or inpatient status on the same date, the services should be reported with codes 99234-99236 as appropriate. Do not report observation discharge (99217) in conjunction with the hospital admission.

When "observation status" is initiated in the course of an encounter in another site of service (e.g., hospital emergency department, practitioner's office, nursing facility) all evaluation and management services provided by the supervising practitioner in conjunction with initiating "observation status" are considered part of the initial observation care when performed on the same date. The observation care level of service reported by the supervising practitioner should include the services related to initiating "observation status" provided in the other sites of service as well as in the observation setting. Evaluation and Management services on the same date provided in sites that are related to initiating "observation status" should NOT be reported separately.

These codes may not be utilized for post-operative recovery if the procedure is considered a part of the surgical "package". These codes apply to all Evaluation and Management services that are provided on the same date of initiating "observation status".

Version 2017 Page 18 of 59

99218 Initial observation care, per day, for the evaluation and management of a patient which requires these 3 key components:

- a detailed or comprehensive history;
- a detailed or comprehensive examination; and
- medical decision making that is straightforward or of low complexity.

Usually the problem(s) requiring admission to "observation status" are of low severity. Physicians typically spend 30 minutes at the bedside and on the patient's hospital floor or unit.

99219 Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of moderate complexity.

Usually the problem(s) requiring admission to "observation status" are of moderate severity. Physicians typically spend 50 minutes at the bedside and on the patient's hospital floor or unit.

99220 Initial observation care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- · a comprehensive examination; and
- medical decision making of high complexity.

Usually the problem(s) requiring admission to "observation status" are of high severity. Physicians typically spend 70 minutes at the bedside and on the patient's hospital floor or unit.

#### SUBSEQUENT OBSERVATION CARE

All levels of subsequent observation care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status (ie, changes in history, physical condition, and response to management) since the last assessment by the physician.

99224 Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- problem focused interval history;
- problem focused examination;
- medical decision making that is straightforward or of low complexity.

Usually, the patient is stable, recovering, or improving. Physicians typically spend 15 minutes at the bedside and on the patient's hospital floor or unit.

99225 Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of moderate complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 25 minutes at the bedside and on the patient's hospital floor or unit.

Version 2017 Page 19 of 59

99226 Subsequent observation care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a detailed interval history;
- a detailed examination;
- medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant complication or a significant new problem. Physicians typically spend 35 minutes at the bedside and on the patient's hospital floor or unit.

#### **HOSPITAL INPATIENT SERVICES**

The following codes are used to report evaluation and management services provided to inpatients.

#### **INITIAL HOSPITAL CARE** - NEW OR ESTABLISHED PATIENT

The following codes are used to report the first hospital encounter with the patient by the admitting practitioner. For subsequent hospital care codes (99231-99233) as appropriate.

99221 Initial hospital care, per day, for the evaluation and management of a patient which requires these three key components:

- a detailed or comprehensive history,
- · a detailed or comprehensive examination, and
- medical decision making that is straightforward or of low complexity.

Usually, the problem(s) requiring admission are of low severity. Practitioners typically spend 30 minutes at the bedside and on the patient's hospital floor or unit.

99222 Initial hospital care, per day, for the evaluation and management of a patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of moderate complexity.

Usually, the problem(s) requiring admission are of moderate severity. Practitioners typically spend 50 minutes at the bedside and on the patient's hospital floor or unit.

99223 Initial hospital care, per day, for the evaluation and management of a patient, which requires these three key components:

- a comprehensive history,
- · a comprehensive examination, and
- · medical decision making of high complexity.

Usually, the problem(s) requiring admission are of high severity. Practitioners typically spend 70 minutes at the bedside and on the patient's hospital floor or unit.

#### SUBSEQUENT HOSPITAL CARE

All levels of subsequent hospital care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status, (i.e., changes in history, physical condition and response to management) since the last assessment by the practitioner.

Version 2017 Page 20 of 59

99231 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:

- · a problem focused interval history,
- a problem focused examination, and/or
- medical decision making that is straightforward or of low complexity.

Usually, the patient is stable, recovering or improving. Practitioners typically spend 15 minutes at the bedside and on the patient's hospital floor or unit.

99232 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:

- an expanded problem focused interval history,
- an expanded problem focused examination, and/or
- medical decision making of moderate complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Practitioners typically spend 25 minutes at the bedside and on the patient's hospital floor or unit.

99233 Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least two of these three key components:

- a detailed interval history,
- a detailed examination, and/or
- medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant complication or a significant new problem. Practitioners typically spend 35 minutes at the bedside and on the patient's hospital floor or unit

# OBSERVATION OR INPATIENT CARE SERVICES (INCLUDING ADMISSION AND DISCHARGE SERVICES)

The following codes are used to report observation or inpatient hospital care services provided to patients admitted and discharged on the same date of service. When a patient is admitted to the hospital from observation status on the same date, the practitioner should report only the initial hospital care code. The initial hospital care code reported by the admitting practitioner should include the services related to the observation status services he/she provided on the same date of inpatient admission.

When "observation status" is initiated in the course of an encounter in another site of service (e.g., hospital emergency department, practitioner's office, nursing facility) all evaluation and management services provided by the supervising practitioner in conjunction with initiating "observation status" are considered part of the initial observation care when performed on the same date. The observation care level of service should include the services related to initiating "observation status" provided in the other sites of service as well as in the observation setting when provided by the same practitioner.

Version 2017 Page 21 of 59

- 99234 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
  - a detailed or comprehensive history;
  - a detailed or comprehensive examination; and
  - medical decision making that is straightforward or of low complexity.

Usually the presenting problem(s) requiring admission are of low severity.

- 99235 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
  - a comprehensive history;
  - a comprehensive examination; and
  - medical decision making of moderate complexity.

Usually the presenting problem(s) requiring admission are of moderate severity.

- 99236 Observation or inpatient hospital care, for the evaluation and management of a patient including admission and discharge on the same date which requires these three key components:
  - a comprehensive history;
  - a comprehensive examination; and
  - medical decision making of high complexity.

Usually the presenting problem(s) requiring admission are of high severity.

#### **HOSPITAL DISCHARGE SERVICES**

The hospital discharge day management codes are to be used to report the total duration of time spent by a practitioner for final hospital discharge of a patient. The codes include, as appropriate, final examination of the patient, discussion of the hospital stay, even if the time spent by the practitioner on that date is not continuous, instructions for continuing care to all relevant caregivers, and preparation of discharge records, prescriptions and referral forms. For patients admitted and discharged from observation or inpatient status on the same date, the service should be reported with codes 99234-99236 as appropriate.

99238 Hospital discharge day management; 30 minutes or less 99239 more than 30 minutes

(These codes are to be utilized by the practitioner to report all services provided to a patient on the date of discharge, if other than the initial date of inpatient status. To report services to a patient who is admitted as an inpatient, and discharge on the same date, see codes 99234-99236 for observation or inpatient hospital care including the admission and discharge of the patient on the same date. To report concurrent care services provided by a practitioner(s) other than the attending practitioner, use subsequent hospital care codes (99231-99233) on the day of discharge.)

#### **EMERGENCY DEPARTMENT SERVICES** - NEW OR ESTABLISHED PATIENT

Version 2017 Page 22 of 59

The following codes are used to report evaluation and management services provided in the emergency department. No distinction is made between new and established patients in the emergency department.

An emergency department is defined as an organized hospital based facility for the provision of unscheduled episodic services to patients who present for immediate medical attention.

The facility must be available 24 hours a day.

99281 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- a problem focused history,
- · a problem focused examination, and
- straightforward medical decision making.

Usually, the presenting problem(s) are self-limited or minor.

99282 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of low complexity.

Usually, the presenting problem(s) are of low to moderate severity.

99283 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- an expanded problem focused history,
- an expanded problem focused examination, and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate severity.

99284 Emergency department visit for the evaluation and management of a patient, which requires these three key components:

- a detailed history;
- a detailed examination; and
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of high severity and require urgent evaluation by the physician but do not pose an immediate significant threat to life or physiologic function.

99285 Emergency department visit for the evaluation and management of a patient, which requires these three key components within the constraints imposed by the urgency of the patient's clinical condition and/or mental status:

- a comprehensive history,
- a comprehensive examination, and
- medical decision making of high complexity.

Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function.

Version 2017 Page 23 of 59

#### **NURSING FACILITY SERVICES**

The following codes are used to report evaluation and management services to patients in Nursing Facilities (formerly called Skilled Nursing Facilities (SNFs), Intermediate Care Facilities (ICFs) or Long Term Care Facilities (LTCFs)).

## INITIAL NURSING FACILITY CARE - NEW OR ESTABLISHED PATIENT

More than one comprehensive assessment may be necessary during an inpatient confinement.

99304 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a detailed or comprehensive history;
- a detailed or comprehensive examination; and
- medical decision making that is straightforward or of low complexity.

Usually, the problem(s) requiring admission are of low severity. Physicians typically spend 25 minutes at the bedside and on the patient's facility floor or unit.

99305 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of moderate complexity.

Usually, the problem(s) requiring admission are of moderate severity. Physicians typically spend 35 minutes at the bedside and on the patient's facility floor or unit.

99306 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components:

- a comprehensive history;
- a comprehensive examination; and
- medical decision making of high complexity.

Usually, the problem(s) requiring admission are of high severity. Physicians typically spend 45 minutes at the bedside and on the patient's facility floor or unit.

## SUBSEQUENT NURSING FACILITY CARE

The following codes are used to report the services provided to residents of nursing facilities who do not require a comprehensive assessment, and/or who have not had a major, permanent change of status.

All levels of subsequent nursing facility care include reviewing the medical record and reviewing the results of diagnostic studies and changes in the patient's status (ie, changes in history, physical condition, and response to management) since the last assessment by the physician.

99307 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a problem focused interval history;
- a problem focused examination;

Version 2017 Page 24 of 59

straightforward medical decision making.

Usually, the patient is stable, recovering, or improving. Physicians typically spend 10 minutes at the bedside and on the patient's facility floor or unit.

99308 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- an expanded problem focused interval history;
- an expanded problem focused examination;
- medical decision making of low complexity.

Usually, the patient is responding inadequately to therapy or has developed a minor complication. Physicians typically spend 15 minutes at the bedside and on the patient's facility floor or unit.

99309 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a detailed interval history;
- a detailed examination;
- medical decision making of moderate complexity.

Usually, the patient has developed a significant complication or a significant new problem. Physicians typically spend 25 minutes at the bedside and on the patient's facility floor or unit.

99310 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components:

- a comprehensive interval history;
- a comprehensive examination;
- medical decision making of high complexity.

The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Physicians typically spend 35 minutes at the bedside and on the patient's facility floor or unit.

#### NURSING FACILITY DISCHARGE SERVICES

The nursing facility discharge day management codes are to be used to report the total duration of time spent by a practitioner for the final nursing facility discharge of patient. The codes include, as appropriate, final examination of the patient, discussion of the nursing facility stay, even if the time spent by the practitioner on that date is not continuous. Instructions are given for continuing care to all relevant caregivers, and preparation of discharge records, prescriptions and referral forms.

99315 Nursing facility discharge day management; 30 minutes or less 99316 more than 30 minutes

Version 2017 Page 25 of 59

# DOMICILIARY, REST HOME (e.g., BOARDING HOME), OR CUSTODIAL CARE SERVICES

The following codes are used to report evaluation and management services in a facility which provides room, board and other personal assistance services, generally on a long-term basis. The facility's services do not include a medical component.

#### **NEW PATIENT**

- 99324 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:
  - a problem focused history,
  - a problem focused examination, and
  - medical decision making that is straightforward.

Usually, the presenting problem(s) are of low severity. Practitioners typically spend 20 minutes with the patient and/or family or caregiver.

- 99325 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:
  - an expanded problem focused history,
  - · an expanded problem focused examination, and
  - medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes with the patient and/or family or caregiver.

- 99326 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:
  - a detailed history,
  - a detailed examination, and
  - medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high complexity. Practitioners typically spend 45 minutes with the patient and/or family or caregiver.

- 99327 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:
  - a comprehensive history,
  - a comprehensive examination, and
  - medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 60 minutes with the patient and/or family or caregiver.

Version 2017 Page 26 of 59

99328 Domiciliary or rest home visit for the evaluation and management of a new patient, which requires these three key components:

- a comprehensive history,
- a comprehensive examination, and
- · medical decision making of high complexity.

Usually, the patient is unstable or has developed a significant new problem requiring immediate physician attention. Practitioners typically spend 75 minutes with the patient and/or family or caregiver.

#### **ESTABLISHED PATIENT**

99334 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- · a problem focused interval history,
- a problem focused examination, and/or
- medical decision making that is straightforward.

Usually, the presenting problem(s) are self-limited or minor. Practitioners typically spend 15 minutes with the patient and/or family or caregiver.

99335 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- an expanded problem focused interval history,
- an expanded problem focused examination, and/or
- medical decision making of low complexity.

Usually, the presenting problem(s) are of low to moderate severity. Practitioners typically spend 25 minutes with the patient and/or family or caregiver.

99336 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a detailed interval history,
- a detailed examination, and/or
- medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes with the patient and/or family or caregiver.

99337 Domiciliary or rest home visit for the evaluation and management of an established patient, which requires at least two of these three key components:

- a comprehensive interval history,
- a comprehensive examination, and
- medical decision making of moderate to high complexity.

Usually, the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate physician attention. Practitioners typically spend 60 minutes with the patient and/or family or caregiver.

Version 2017 Page 27 of 59

## **HOME SERVICES**

The following codes are used to report evaluation and management services provided in a private residence.

#### **NEW PATIENT**

- 99341 Home visit for the evaluation and management of a new patient, which requires these three key components:
  - a problem focused history,
  - · a problem focused examination, and
  - medical decision making that is straightforward.

Usually the presenting problem(s) are of low severity. Practitioners typically spend 20 minute face-to-face with the patient and/or family.

- 99342 Home visit for the evaluation and management of a new patient, which requires these three key components:
  - an expanded problem focused history,
  - an expanded problem focused examination, and
  - · medical decision making of low complexity.

Usually, the presenting problem(s) are of moderate severity. Practitioners typically spend 30 minutes face-to-face with the patient and/or family.

- 99343 Home visit for the evaluation and management of a new patient, which requires these three key components:
  - a detailed history,
  - · a detailed examination, and
  - medical decision making of moderate complexity.

Usually, the presenting problem(s) are of moderate to high severity. Practitioners typically spend 45 minutes face-to-face with patient and/or family.

- 99344 Home visit for the evaluation and management of a new patient, which requires these three key components:
  - a comprehensive history,
  - a comprehensive examination; and
  - medical decision making of moderate complexity.

Usually the presenting problem(s) are of high severity. Practitioners typically spend 60 minutes face-to-face with the patient and/or family.

- 99345 Home visit for the evaluation and management of a new patient, which requires these three key components:
  - a comprehensive history,
  - · a comprehensive examination; and
  - medical decision making of high complexity.

Usually the patient is unstable or has developed a significant new problem requiring immediate Practitioner attention. Practitioners typically spend 75 minutes face-to-face with the patient and/or family.

Version 2017 Page 28 of 59

#### **ESTABLISHED PATIENT**

- 99347 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  - a problem focused interval history;
  - a problem focused examination and
  - straightforward medical decision making.

Usually the presenting problem(s) are self-limited or minor. Practitioners typically spend 15 minutes face-to-face with the patient and/or family.

- 99348 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  - an expanded problem focused interval history;
  - an expanded problem focused examination;
  - medical decision making of low complexity.

Usually the presenting problem(s) are of low to moderate severity. Practitioners typically spend 25 minutes face-to-face with the patient and/or family.

- 99349 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  - a detailed interval history;
  - a detailed examination;
  - medical decision making of moderate complexity.

Usually the presenting problem(s) are of moderate to high severity. Practitioners typically spend 40 minutes face-to-face with the patient and/or family.

- 99350 Home visit for the evaluation and management of an established patient, which requires at least two of these three key components:
  - a comprehensive interval history;
  - a comprehensive examination;
  - medical decision making of moderate to high complexity.

Usually the presenting problem(s) are of moderate to high severity. The patient may be unstable or may have developed a significant new problem requiring immediate practitioner attention. Practitioners typically spend 60 minutes face-to-face with the patient and/or family.

Version 2017 Page 29 of 59

#### PREVENTIVE MEDICINE SERVICES

The following codes are used to report well visit services.

#### **NEW PATIENT**

99381 Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)

99382	early childhood (age 1 through 4 years)
99383	late childhood (age 5 through 11 years)
99384	adolescent (age 12 through 17 years)
99385	18-39 years
99386	40-64 years
99387	65 years and older

#### **ESTABLISHED PATIENT**

99391 Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant

	(age younger than 1 year)
99392	early childhood (age 1 through 4 years)
99393	late childhood (age 5 through 11 years)
99394	adolescent (age 12 through 17 years)
99395	18 - 39 years
99396	40 - 64 years
99397	65 years and older

#### COUNSELING RISK FACTOR REDUCTION AND BEHAVIOR CHANGE INTERVENTION

#### BEHAVIOR CHANGE INTERVENTIONS, INDIVIDUAL

99406 Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes

99407 intensive, greater than 10 minutes

Version 2017 Page 30 of 59

#### **NEWBORN CARE SERVICES**

The following codes are used to report the services provided to newborns (birth through the first 28 days) in several different settings. Use of the newborn codes is limited to the initial care of the newborn in the first days after birth prior to home discharge.

- 99460 Initial hospital or birthing center care, per day, for evaluation and management of normal newborn infant
   99462 Subsequent hospital care, per day, for evaluation and management of normal newborn
   99463 Initial hospital or birthing center care, per day, for evaluation and management of normal
  - newborn infant admitted and discharged on the same date

## LABORATORY SERVICES PERFORMED IN THE OFFICE

Certain laboratory procedures specified below are eligible for direct nurse practitioner reimbursement when performed in the office of the nurse practitioner in the course of treatment of her own patients.

The nurse practitioner must be registered with the federal Health Care Finance Administration (HCFA) to perform laboratory procedures as required by the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA '88).

Procedures other than those specified must be performed by a laboratory, holding a valid clinical laboratory permit in the commensurate laboratory, specialty issued by the New York State Department of Health or, where appropriate, the New York City Department of Health.

For detection of pregnancy, use code 81025.

Procedure code 85025, complete blood count (CBC), may not be billed with its component codes 85007, 85013, 85018, 85041 or 85048.

81000 Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy

81001 automated, with microscopy
81002 non-automated, without microscopy
81003 automated, without microscopy
81015 Urinalysis; microscopic only

81025 Urine pregnancy test, by visual color comparison methods

83655 Lead

85007 Blood count; blood smear, microscopic examination with manual differential WBC count

85013 spun microhematocrit 85018 hemoglobin (Hgb)

complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated

differential WBC count

85041 red blood cell (RBC) automated

85048 leukocyte (WBC), automated

85651 Sedimentation rate, erythrocyte; non-automated

Version 2017 Page 31 of 59

#### **Nurse Practitioner Procedure Codes**

85652	automated
86701	Antibody; HIV-1
86703	HIV-1 and HIV-2, single result
87081	Culture, presumptive, pathogenic organisms, screening only;
87651	Streptococcus, group A, amplified probe technique
87806	HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies
87880	Streptococcus, group A

NOTE: Medicare reimburses for these services at 100 percent. No Medicare co-insurance payments may be billed for the above listed procedure codes.

## DRUGS AND DRUG ADMINISTRATION

#### **IMMUNIZATIONS**

If a significantly separately identifiable Evaluation and Management services (eg, office service, preventative medicine services) is performed, the appropriate E/M code should be reported in addition to the vaccine and toxoid codes.

Immunizations are usually given in conjunction with a medical service. When an immunization is the only service performed, a minimal service may be listed in addition to the injection. Immunization procedures include reimbursement for the supply of materials and administration.

Reimbursement for drugs (including vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

#### **IMMUNE GLOBULINS**

Immune globulin products listed here include broad-spectrum and anti-infective immune globulins, antitoxins, and various isoantibodies.

90291 90371	Cytomegalovirus immune globulin (CMV-lgIV), human, for intravenous use Hepatitis B immune globulin (HBlg), human, for intramuscular use
90375	Rabies immune globulin (Rlg), human, for intramuscular and/or subcutaneous use (150 IU/ml)
90376	Rabies immune globulin, heat-treated (RIg-HT), human, for intramuscular and/or subcutaneous use
90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each
90384	Rho(D) immune globulin (Rhlg), human, full-dose, for intramuscular use
90385	Rho(D) immune globulin (Rhlg), human, mini-dose, for intramuscular use

Version 2017 Page 32 of 59

#### **Nurse Practitioner Procedure Codes**

- 90386 Rho(D) immune globulin (RhlgIV), human, for intravenous use
- 90389 Tetanus immune globulin (Tlg), human, for intramuscular use
- 90393 Vaccinia immune globulin, human, for intramuscular use
- 90396 Varicella-zoster immune globulin, human, for intramuscular use
- 90399 Unlisted immune globulin

#### IMMUNIZATION ADMINISTRATION FOR VACCINES/TOXOIDS

- 90460 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered)
- 90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)
- 90472 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (list separately in addition to code for primary procedure))
- 90473 Immunization administration by intranasal or oral route; one vaccine (single or combination vaccine/toxoid)
- 90474 Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (list separately in addition to code for primary procedure)

#### **VACCINES/TOXOIDS**

For dates of service on or after 7/1/03 when immunization materials are supplied by the Vaccines for Children Program (VFC), bill using the procedure code that represents the immunization(s) administered and **append modifier –SL State Supplied Vaccine** to receive the VFC administration fee. See Modifier Section for further information.

For administration of vaccines supplied by VFC, including influenza and pneumococcal administration, providers will be required to bill vaccine administration code 90460. Providers must continue to bill the specific vaccine code with the "SL" modifier on the claim (payment for "SL" will be \$0.00). If an administration code is billed without a vaccine code with "SL", the claim will be denied. For reimbursement purposes, the administration of the components of a combination vaccine will continue to be considered as one vaccine administration. More than one vaccine administration is reimbursable under 90460 on a single date of service.

**NOTE**: The maximum fees for immunization injection codes are adjusted periodically by the State to reflect the current acquisition cost of the antigen. For immunizations not supplied by the VFC Program insert acquisition cost in amount charged field on claim form. For codes listed **BR/Report required**, also attach itemized invoice to claim form.

To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the exact vaccine product administered needs to be reported with modifier -SL. Multiple codes for a particular vaccine are provided in CPT when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration.

Version 2017 Page 33 of 59

Separate codes are available for combination vaccines (eg, DTP-Hib, DtaP-Hib, HepB-Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the Unlisted procedure code should be reported, until a new code becomes available.

- 90585 Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use
- 90586 Bacillus Calmette-Guerin vaccine (BCG) for bladder cancer, live, for intravesical use
- 90620 Meningococcal recombinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use
- 90621 Meningococcal recombinant lipoprotein vaccine, Serogroup B, 2 or 3 dose schedule, for intramuscular use
- 90630 Influenza vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use
- 90632 Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
- 90633 Hepatitis A vaccine (Hep A),pediatric/adolescent dosage-2 dose schedule, for intramuscular use
- 90636 Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use
- 90647 Haemophilus influenza type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use
- 90648 Haemophilus influenza type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use
- 90649 Human Papillomavirus vaccine, types 6, 11, 16, 18 quadrivalent (4vHPV), 3 dose schedule, for intramuscular use
- 90650 Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use
- 90651 Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 3 dose schedule, for intramuscular use
- 90654 Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use
- 90655 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use
- 90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5mL dosage, for intramuscular use
- 90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use
- 90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage for intramuscular use
- 90660 Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use
- 90661 Influenza virus vaccine trivalent(ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
- 90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
- 90670 Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use
- 90673 Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA (RIV3), hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
- 90674 Influenza virus vaccine; quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
- 90675 Rabies vaccine, for intramuscular use
- 90676 Rabies vaccine, for intradermal use
- 90680 Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use
- 90681 Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use

Version 2017 Page 34 of 59

#### **Nurse Practitioner Procedure Codes**

- 90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use
- 90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
- 90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
- 90690 Typhoid vaccine, live, oral
- 90691 Typhoid vaccine, Vi capsular polysaccharide (ViCPs), for intramuscular use
- 90696 Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine, (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use
- 90698 Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type B, and inactivated poliovirus vaccine, (DTaP –IPV/Hib), for intramuscular use
- 90700 Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use
- 90702 Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use
- 90707 Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use
- 90710 Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use
- 90713 Poliovirus vaccine, inactivated, (IPV), for subcutaneous or intramuscular use
- 90714 Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use
- 90715 Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use
- 90716 Varicella virus vaccine (VAR), live, for subcutaneous use
- 90717 Yellow fever vaccine, live, for subcutaneous use
- 90723 Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, (DTaP-HepB-IPV), for intramuscular use
- 90732 Pneumococcal polysaccharide vaccine, 23-valent, (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use
- 90733 Meningococcal polysaccharide vaccine, serogroups A,C,Y,W-135,quadrivalent (MPSV4),for subcutaneous use
- 90734 Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use
- 90736 Zoster (shingles) vaccine, (HZV), live, for subcutaneous injection
- 90738 Japanese encephalitis virus vaccine, inactivated, for intramuscular use
- 90740 Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use
- 90743 Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use
- 90744 Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use
- 90746 Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
- 90747 Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use
- 90748 Hepatitis B and Haemophilus influenza type b (Hib-HepB), for intramuscular use
- 90749 Unlisted vaccine/toxoid

Version 2017 Page 35 of 59

#### DRUGS ADMINISTERED OTHER THAN ORAL METHOD

The following list of drugs can be injected either subcutaneous, intramuscular or intravenously. A listing of chemotherapy drugs can be found in the Chemotherapy Section.

New York State Medicaid's policy for coverage of drugs administered by subcutaneous, intramuscular or intravenous methods in the physician's office is as follows: These drugs are covered for FDA approved indications and those recognized off-label indications listed in the drug compendia (the American Hospital Formulary Service Drug Information, United States Pharmacopeia-Drug Information, the DrugDex information system or Facts and Comparisons). In the absence of such a recognized indication, an approved Institutional Review Board (IRB) protocol would be required with documentation maintained in the patient's clinical file. Drugs are not covered for investigational or experimental use.

Reimbursement for drugs (including vaccines and immune globulins) furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice.

New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

**NOTE**: The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert acquisition cost per dose in amount charged field on claim form. For codes listed as BR in the Fee Schedule, also attach an itemized invoice to claim form.

#### THERAPEUTIC INJECTIONS (Maximum fee includes cost of materials)

J0129	Abatacept, 10 mg (Administered under direct physician supervision, not for self-administration)
10425	· · · · · · · · · · · · · · · · · · ·
J0135	,
J0153	Adenosine, 1 mg
	(Not to be used to report any adenosine phosphate compounds, instead use unlisted code)
J0171	Adrenalin, epinephrine, 0.1 mg
J0180	Agalsidase beta, 1 mg
J0202	Alemtuzumab, 1 mg
J0205	Alglucerase, per 10 units
J0207	Amifostine, 500 mg
J0210	Methyldopate HCI, up to 250 mg
J0215	Alefacept, 0.5 mg

(Administered under direct physician supervision, not for self-administration)

J0256 Alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg

J0275 Alprostadil urethral suppository

J0270

Alprostadil, per 1.25 mcg

Version 2017 Page 36 of 59

JO280 Amipohylline, up to 250 mg JO293 Ampicillin sodium, up to 500 mg JO294 Ampicillin sodium, up to 500 mg JO300 Amobarbital, up to 125 mg JO360 Hydralazine HCl, up to 20 mg JO380 Metaraminol bitartrate, per 10 mg JO390 Achibronyin, 500 mg JO456 Azithromycin, 500 mg JO476 Atropine sulfate, 0.01 mg JO470 Dimercaprol, per 100 mg JO500 Dicyclomine HCl, up to 20 mg JO500 Dicyclomine HCl, up to 20 mg JO500 Dicyclomine HCl, up to 20 mg JO515 Benztropine mesylate, per 1 mg JO500 Penicillin G benzathine and penicillin G procaine, 100,000 units JO581 Penicillin G benzathine, 100,000 units JO583 Penicillin G benzathine, 100,000 units JO584 RimabotulinumtoxinaA, 5 units JO585 RimabotulinumtoxinaB, 100 units JO586 AbobtulinumtoxinaB, 100 units JO587 RimabotulinumtoxinaB, 100 units JO588 Calcitrin Glocium, up to 400 units JO600 Calcium gluconate, per 10 ml JO600 Calciton in salmon, up to 400 units JO638 Calcitriol, 0.1 mcg JO640 Leucovorin calcium, per 50 mg JO694 Leucovorin calcium, up to 500 mg JO694 Cefezolin sodium, up to 500 mg JO696 Cefezolin sodium, up to 500 mg JO697 Cefezolin sodium, up to 500 mg JO698 Cefetavine sodium, per 250 mg JO699 Cefetavine sodium, per 250 mg JO699 Cefetavine sodium, per 500 mg JO690 Cefezolin sodium, up to 1 gm JO710 Cephapirin sodium, per 500 mg JO710 Cophapirin sodium, per 500 mg JO710 Cophapirin sodium, per 500 mg JO710 Cibitorin or intravenous infusion, 200 mg JO710 Cibitorin chate sodium, up to 1 gm JO710 Colistimethate sodium, up to 150 mg JO710 Coloroproproproproproproproproproproproprop		(Administered upder direct physician cup anticipe, not for cell administration)
J0290 Ampicillin sodium, up to 500 mg J0295 Ampicillin sodium, up to 125 mg J0300 Amobarbital, up to 125 mg J0300 Hydralazine HCl, up to 20 mg J0380 Metaraminol bitartrate, per 10 mg J0390 Chloroquine HCl, up to 250 mg J0461 Atropine sulfate, 0.01 mg J0470 Dimercaprol, per 100 mg J0510 Benztropine mesylate, per 1 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0585 Penicillin G benzathine and penicillin G procaine, 100,000 units J0586 ApoblulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinaA, 5 units J0588 Rimabotulinumtoxina, 100 units J0600 Calcium gluconate, per 10 ml J0610 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0691 Cefezolin sodium, up to 500 mg J0692 Cefezolin sodium, up to 500 mg J0693 Cefotaxime sodium, per 250 mg J0694 Cefotaxime sodium, per 250 mg J0695 Cefotaxime sodium, per 50 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per 500 mg J0709 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Chloramphenicol sodium succinate, up to 1 gm J0713 Ceftazidime, per 500 mg J0714 Cidofovir, 375 mg J0715 Colitimethate sodium, up to 150 mg J0716 Coleine phosphate, per 30 mg J0717 Colistimethate sodium, up to 150 mg J0718 Coleine phosphate, per 30 mg J0719 Colistimethate sodium, up to 150 mg J0710 Colistimethate sodium, up to 150 mg J0711 Colistimethate sodium, up to 150 mg J0712 Colistimethate sodium, up to 150 mg J0713 Colistimethate sodium, up to 150 mg J0714 Colistimethate sodium, up to 150 mg	10200	(Administered under direct physician supervision, not for self-administration)
J0295 Ampicillin sodium/sulbactam sodium, per 1.5 gm J0300 Amobarbital, up to 125 mg J0360 Hydralazine HCl, up to 20 mg J0380 Metaraminol bitartrate, per 10 mg J0390 Chloroquine HCl, up to 250 mg J0456 Azithromycin, 500 mg J0461 Atropine sulfate, 0.01 mg J0470 Dimercaprol, per 100 mg J0475 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0586 AbobtulinumtoxinaA, 1 unit J0586 AbobtulinumtoxinaA, 5 units J0587 RimabotulinumtoxinaB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, 0.5 mg J0641 Levoleucovorin calcium, 0.5 mg J0694 Cefezolin sodium, up to 500 mg J0695 Cefezolin sodium, up to 500 mg J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per 500 mg J0700 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Ceftazidime, per 500 mg J0713 Ceftazidime, per 500 mg J0714 Ceftazidime, per 500 mg J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0741 Cidofovir, 375 mg J0742 Colcien phosphate, per 30 mg J0743 Codeine phosphate, per 30 mg J0744 Colcien phosphate, per 30 mg J0755 Colcien phosphate, per 30 mg J0760 Prochlorperazine, up to 10 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg		
J0300 Amobarbital, up to 125 mg J0360 Hydralazine HCl, up to 20 mg J0390 Metaraminol bitartrate, per 10 mg J0390 Chloroquine HCl, up to 250 mg J0451 Azithromycin, 500 mg J0461 Atropine sulfate, 0.01 mg J0472 Dimercaprol, per 100 mg J0473 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0538 Penicillin G benzathine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 1 unit J0587 RimabotulinumtoxinaA, 5 units J0680 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0641 Levoleucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, per 50 mg J0694 Cefozitin sodium, up to 500 mg J0695 Ceftriaxone sodium, per 250 mg J0696 Ceftriaxone sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Chloramphenicol sodium succinate, up to 1 gm J0720 Chloramphenicol sodium succinate, up to 1 gm J0721 Chorionic gonadotropin, per 1,000 USP units J0744 Cidofovir, 375 mg J0745 Codeine phosphate, per 30 mg J0746 Codeine phosphate, per 30 mg J0777 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg		,
J0360 Hydralazine HCl, up to 20 mg J0380 Metaraminol bitartrate, per 10 mg J0390 Chloroquine HCl, up to 250 mg J0461 Atropine sulfate, 0.01 mg J0471 Dimercaprol, per 100 mg J0472 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0581 Penicillin G benzathine, 100,000 units J0585 Penicillin G benzathine, 100,000 units J0586 AbobotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 1 unit J0587 RimabotulinumtoxinaB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0631 Calcitonin salmon, up to 500 mg J0641 Levoleucovorin calcium, per 50 mg J0694 Levoleucovorin calcium, up to 500 mg J0695 Cefezolin sodium, 1 gm J0696 Cefezolin sodium, 1 gm J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per 250 mg J0709 Sterile cefuroxime sodium, per 750 mg J0710 Cephapirin sodium, up to 1 gm J0711 Cephapirin sodium, up to 1 gm J0712 Ceftizoxime sodium, per 500 mg J0713 Ceftizoxime sodium, per 500 mg J0714 Ceftazidime, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0730 Cidofovir, 375 mg J0740 Cidofovir, 375 mg J0740 Cidofovir, 375 mg J0740 Codeine phosphate, per 30 mg J0750 Codeine phosphate, per 30 mg J0760 Prochlorperazine, up to 10 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 150 mg J0780 Prochlorperazine, up to 150 mg		, ,
J0380 Metaraminol bitartrate, per 10 mg J0390 Chloroquine HCl, up to 250 mg J0461 Atropine sulfate, 0.01 mg J0470 Dimercaprol, per 100 mg J0475 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0565 Penicillin G benzathine, 100,000 units J0566 ConabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaB, 100 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, per 500 mg J0694 Cefoxitin sodium, up to 500 mg J0695 Cefezolin sodium, up to 500 mg J0696 Ceftriaxone sodium, per 250 mg J0697 Ceftriaxone sodium, per gm J0708 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Ceftazidime, per 500 mg J0713 Ceftzoxime sodium, per 500 mg J0714 Ceftoxime sodium, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0716 Ceftoxime sodium, per 500 mg J0717 Ceftizoxime sodium, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Cidofovir, 375 mg J0745 Codeine phosphate, per 30 mg J0746 Crockine prosphate, per 30 mg J0770 Colistimethate sodium, up to 10 mg J0780 Prochlorperazine, up to 10 mg		·
J0390 Chloroquine HCl, up to 250 mg J0456 Azithromycin, 500 mg J0461 Atropine sulfate, 0.01 mg J0470 Dimercaprol, per 100 mg J0475 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0538 Penicillin G benzathine and penicillin G procaine, 100,000 units J0546 Penicillin G benzathine, 100,000 units J0547 Penicillin G benzathine, 100,000 units J0548 OnabotulinumtoxinaA, 1 unit J0548 AbobotulinumtoxinaA, 5 units J0560 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Levoleucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0642 Levoleucovorin calcium, up to 500 mg J0694 Cefoxitin sodium, up to 500 mg J0696 Cefezolin sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0709 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftizoxime sodium, per 500 mg J0712 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Cidofovir, 375 mg J0745 Codeine phosphate, per 30 mg J0750 Crockimethate sodium, up to 10 mg J0760 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		· ·
J0456 Azithromycin, 500 mg J0461 Atropine sulfate, 0.01 mg J0470 Dimercaprol, per 100 mg J0475 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinaA, 5 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitrol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, up to 500 mg J0691 Cefezolin sodium, up to 500 mg J0692 Cefoxitin sodium, up to 500 mg J0693 Sterile cefuroxime sodium, per 750 mg J0694 Cefoxitin sodium, per gm J0695 Cefotaxime sodium, per gm J0709 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Chloramphenicol sodium succinate, up to 1 gm J0713 Ceftazidime, per 500 mg J0714 Cidofovir, 375 mg J0744 Cidofovir, 375 mg J0745 Codeine phosphate, per 30 mg J0780 Prochlorperazine, up to 10 mg		·
J0461 Atropine sulfate, 0.01 mg J0470 Dimercaprol, per 100 mg J0471 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0510 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0521 Benzitropine mesylate, per 1 mg J0522 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0538 Penicillin G benzathine and penicillin G procaine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0680 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0694 Cefezolin sodium, up to 500 mg J0695 Cefezolin sodium, up to 500 mg J0696 Cefriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0710 Cephapirin sodium, up to 1 gm J0711 Cephapirin sodium, up to 1 gm J0712 Chloramphenicol sodium succinate, up to 1 gm J0713 Ceftizoxime sodium, per 500 mg J0714 Ceftizoxime sodium, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0716 Coficinorin consolium succinate, up to 1 gm J0717 Collotimethate sodium, up to 150 mg J0744 Cidofovir, 375 mg J0745 Codeine phosphate, per 30 mg J0750 Colistimethate sodium, up to 150 mg J0760 Colistimethate sodium, up to 150 mg J0770 Colistimethate sodium, up to 150 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		· · · · · · · · · · · · · · · · · · ·
J0470 Dimercaprol, per 100 mg J0475 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0538 Penicillin G benzathine and penicillin G procaine, 100,000 units J0581 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0600 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0620 Calcitioni, 0.1 mcg J0630 Calcitrol, 0.1 mcg J0641 Leucovorin calcium, per 50 mg J0642 Leucovorin calcium, up to 500 mg J0694 Cefezolin sodium, up to 500 mg J0695 Cefezolin sodium, 1 gm J0696 Ceffixianone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0709 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftizoxime sodium, up to 500 mg J0710 Ceftizoxime sodium, per 500 mg J0710 Coftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0713 Ceftizoxime sodium, per 500 mg J0724 Ciprofloxacin for intravenous infusion, 200 mg J0734 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0776 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		· · · · · · · · · · · · · · · · · · ·
J0475 Baclofen, 10 mg J0500 Dicyclomine HCl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0520 Penicillin G benzathine and penicillin G procaine, 100,000 units J0581 Penicillin G benzathine, 100,000 units J0582 OnabotulinumtoxinaA, 1 unit J0583 OnabotulinumtoxinaA, 5 units J0584 Rimabotulinumtoxina, 100 units J0601 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0631 Calcitriol, 0.1 mcg J0641 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg Cefezolin sodium, up to 500 mg Cefezolin sodium, per gm J0691 Cefotxime sodium, per gm J0692 Cefotaxime sodium, per gm J0703 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftizoxime sodium, per 500 mg J0712 Ceftizoxime sodium, per 500 mg J0713 Ceftizoxime sodium, per 500 mg J0714 Ceftizoxime sodium, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0716 Cohoramphenicol sodium succinate, up to 1 gm J0717 Cohoramphenicol sodium succinate, up to 1 gm J0718 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0776 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		,
J0500 Dicyclomine HČl, up to 20 mg J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0581 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium glycerophosphate and calcium lactate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0690 Cefezolin sodium, up to 500 mg J0691 Sterile cefuroxime sodium, per 750 mg J0693 Sterile cefuroxime sodium, per 750 mg J0694 Cefotaxime sodium, per gm J0705 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Ceftizoxime sodium, per 500 mg J0713 Ceftizoxime sodium, per 500 mg J0714 Ceftizoxime sodium, per 1,000 USP units J0724 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0741 Codeine phosphate, per 30 mg J0742 Codeine phosphate, per 30 mg J0743 Codeine phosphate, per 30 mg J0760 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		• • •
J0515 Benztropine mesylate, per 1 mg J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0631 Calcitonin salmon, up to 500 mg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0691 Cefezolin sodium, up to 500 mg J0692 Cefotaxime sodium, per 250 mg J0693 Sterile cefuroxime sodium, per 750 mg J0694 Cefotaxime sodium, per gm J0705 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Ceftizoxime sodium, per 500 mg J0713 Ceftizoxime sodium, per 500 mg J0714 Ceftizoxime sodium, per 1,000 USP units J0720 Chloramphenicol sodium succinate, up to 1 gm J0715 Ceftizoxime sodium, per 1,000 USP units J0740 Cidofovir, 375 mg J0741 Cidofovir, 375 mg J0742 Cidofovir, 375 mg J0743 Codeine phosphate, per 30 mg J0744 Cidofovired in travenous infusion, 200 mg J0755 Codeine phosphate, per 30 mg J0776 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0520 Bethanechol chloride, myotonachol or urecholine, up to 5 mg J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaB, 100 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0694 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Retamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftazidime, per 500 mg J0712 Ceftizoxime sodium, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0740 Cidofovir, 375 mg J0741 Codeine phosphate, per 30 mg J0742 Codeine phosphate, per 30 mg J0750 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		, , ,
J0558 Penicillin G benzathine and penicillin G procaine, 100,000 units J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinaB, 100 units J0600 Edetae calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0691 Levoleucovorin calcium, 0.5 mg J0694 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, per 250 mg J0695 Cefezolin sodium, per gm J0696 Ceftriaxone sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0711 Ceftizoxime sodium, per 500 mg J0712 Ceftizoxime sodium, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0741 Cidofovir, 375 mg J0742 Codeine phosphate, per 30 mg J0743 Codeine phosphate, per 30 mg J0750 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0780 Cosyntropin (Cortrosyn), 0.25 mg		, , , , ,
J0561 Penicillin G benzathine, 100,000 units J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, per 250 mg J0695 Ceftriaxone sodium, per 750 mg J0696 Ceftriaxone sodium, per 750 mg J0697 Sterile cefuroxime sodium, per 750 mg J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0741 Ciprofloxacin for intravenous infusion, 200 mg J0742 Codeine phosphate, per 30 mg J0743 Codeine phosphate, per 30 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0585 OnabotulinumtoxinaA, 1 unit J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitroil, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0694 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		·
J0586 AbobotulinumtoxinaA, 5 units J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, per 250 mg J0695 Sterile cefuroxime sodium, per 750 mg J0696 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0741 Ciprofloxacin for intravenous infusion, 200 mg J0742 Codeine phosphate, per 30 mg J0773 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0587 RimabotulinumtoxinB, 100 units J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0726 Chloramphenicol sodium succinate, up to 1 gm J0727 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		, ,
J0600 Edetate calcium disodium, up to 1000 mg J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0710 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0711 Ceftazidime, per 500 mg J0712 Cehorionic gonadotropin, per 500 mg J0713 Ceftizoxime sodium, up to 1 gm J0714 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		·
J0610 Calcium gluconate, per 10 ml J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0720 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0620 Calcium glycerophosphate and calcium lactate, per 10 ml J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0630 Calcitonin salmon, up to 400 units J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0720 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0636 Calcitriol, 0.1 mcg J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		• • • • • • • • • • • • • • • • • • • •
J0640 Leucovorin calcium, per 50 mg J0641 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		
J0691 Levoleucovorin calcium, 0.5 mg J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		·
J0690 Cefezolin sodium, up to 500 mg J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		• 1
J0694 Cefoxitin sodium, 1 gm J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0720 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg		·
J0696 Ceftriaxone sodium, per 250 mg J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0694	• •
J0697 Sterile cefuroxime sodium, per 750 mg J0698 Cefotaxime sodium, per gm J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0696	·
J0702 Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0697	·
J0710 Cephapirin sodium, up to 1 gm J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0698	Cefotaxime sodium, per gm
J0713 Ceftazidime, per 500 mg J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0702	Betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
J0715 Ceftizoxime sodium, per 500 mg J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0710	Cephapirin sodium, up to 1 gm
J0720 Chloramphenicol sodium succinate, up to 1 gm J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0713	Ceftazidime, per 500 mg
J0725 Chorionic gonadotropin, per 1,000 USP units J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0715	Ceftizoxime sodium, per 500 mg
J0740 Cidofovir, 375 mg J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0720	Chloramphenicol sodium succinate, up to 1 gm
J0744 Ciprofloxacin for intravenous infusion, 200 mg J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0725	Chorionic gonadotropin, per 1,000 USP units
J0745 Codeine phosphate, per 30 mg J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0740	Cidofovir, 375 mg
J0770 Colistimethate sodium, up to 150 mg J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0744	Ciprofloxacin for intravenous infusion, 200 mg
J0780 Prochlorperazine, up to 10 mg J0834 Cosyntropin (Cortrosyn), 0.25 mg	J0745	, , ,
J0834 Cosyntropin (Cortrosyn), 0.25 mg		·
J0875 Dalbavancin, 5 mg		
	J0875	Dalbavancin, 5 mg

Version 2017 Page 37 of 59

J0881	Darbepoetin alfa, 1 mcg (Non-ESRD use)
J0885	Epoetin alfa, (Non-ESRD use), 1000 units
J0888	Epoetin beta, 1 mcg (Non-ESRD-use)
J0895	Deferoxamine mesylate, 500 mg
J0945	Brompheniramine maleate, per 10 mg
J1000	Depo-estradiol cypionate, up to 5 mg
J1020	Methylprednisolone acetate, 20 mg
J1030	Methylprednisolone acetate, 40 mg
J1040	Methylprednisolone acetate, 80 mg
J1050	Injection, medroxyprogesterone acetate, 1 mg
J1071	Testosterone cypionate, 1 mg
J1094	Dexamethasone acetate, 1 mg
J1100	Dexamethasone sodium phosphate, 1 mg
J1110	Dihydroergotamine mesylate, per 1 mg
J1120	Acetazolamide sodium, up to 500 mg
J1160	Digoxin, up to 0.5 mg
J1165	Phenytoin sodium, per 50 mg
J1170	Hydromorphone, up to 4 mg
J1180	Dyphylline, up to 500 mg
J1190	Dexrazoxane HCl, per 250 mg
J1200	Diphenhydramine HCl, up to 50 mg
J1205	Chlorothiazide sodium, per 500 mg
J1212	DMSO, dimethyl sulfoxide, 50%, 50 ml
J1230	Methadone HCI, up to 10 mg
J1240	Dimenhydrinate, up to 50 mg
J1260	Dolasetron mesylate, 10 mg
J1300	Eculizumab, 10 mg
J1320	Amitriptyline HCl, up to 20 mg
J1322	Elosulfase alfa, 1 mg
J1330	Ergonovine maleate, up to 0.2 mg
J1364	Erythromycin lactobionate, per 500 mg
J1380	Estradiol valerate, up to 10 mg
J1410	Estrogen conjugated, per 25 mg
J1435	Estrone, per 1 mg
J1436	Etidronate disodium, per 300 mg Etanercept, 25 mg
J1438	(Administered under direct physician supervision, not self-administered)
J1439	Ferric Carboxymaltose, 1 mg
J1442	Filgrastim (G CSF), excludes biosimilars, 1 microgram
J1447	The Filgrastim, 1 microgram
J1450	Fluconazole, 200 mg
J1452	Fomivirsen sodium, intraocular, 1.65 mg
	Fosaprepitant, 1 mg
	Foscarnet sodium, per 1000 mg
	Coloulfoce 4 mg

Version 2017 Page 38 of 59

J1458 Galsulfase, 1 mg

J1459 Immune globulin (Privigen), intravenous, non lyophilized (e.g. liquid), 500 mg J1460 Gamma globulin, intramuscular, 1 cc J1556 Immune Globulin (Bivigam), 500 mg J1560 Gamma globulin, intramuscular, over 10 cc J1561 Immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g. liquid), 500 mg J1562 Immune globulin (Vivaglobin), 100 mg J1566 Immune globulin, intravenous, lyophilized (e.g. powder), not otherwise specified, 500 mg Immune globulin, (Octagam), intravenous, non-lyophilized (e.g. liquid), 500 mg J1568 Immune globulin, (Gammagard Liquid), non-lyophilized, (e.g. liquid), 500 mg J1569 J1570 Ganciclovir sodium, 500 mg Immune globulin, (flebogamma/flebogamma DIF), intravenous, non-lyophilized (e.g. liquid), J1572 500 ma Hepatitis B immune globulin (HepaGam B), intravenous, 0.5 ml J1573 Immune Globulin/Hyaluronidase (HYQVIA), 100 mg J1575 Garamycin, gentamicin, up to 80 mg J1580 Glatiramer acetate, 20 mg J1595 Immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified, 500 mg J1599 J1600 Gold sodium thiomalate, up to 50 mg Golimumab, per 1 mg for Intravenous use J1602 J1610 Glucagon HCl, per 1 mg Gonadorelin HCI, per 100 mcg J1620 Granisetron HCI, 100 mcg J1626 Haloperidol, up to 5 mg J1630 Haloperidol decanoate, per 50 mg J1631 Heparin sodium, (heparin lock flush), per 10 units J1642 Heparin sodium, per 1000 units J1644 Dalteparin sodium, per 2500 IU J1645 Fondaparinux sodium, 0.5 mg J1652 Tinzaparin sodium, 1000 IU J1655 J1710 Hydrocortisone sodium phosphate, up to 50 mg Hydrocortisone sodium succinate, up to 100 mg J1720 Hydroxyprogesterone caproate, 1 mg J1725 Diazoxide, up to 300 mg J1730 Ibandronate sodium, 1 mg J1740 Injection, ibuprofen, 100 mg J1741 J1745 Infliximab, 10 mg J1750 Iron dextran, 50 mg J1756 Iron sucrose, 1 mg J1786 Imiglucerase, 10 units J1790 Droperidol, up to 5 mg J1800 Propranolol HCl, up to 1 mg J1815 Insulin, per 5 units Insulin (i.e., insulin pump) per 50 units J1817

Version 2017 Page 39 of 59

J1826

Interferon beta-1a, 30 mcg

(Administered under direct physician supervision, not for self-administration)

14000	laterfaces between the O.O.S. was
J1830	
14040	(Administered under direct physician supervision, not for self-administration)
J1840	Kanamycin sulfate, up to 500 mg
J1850	Kanamycin sulfate, up to 75 mg
J1885	Ketorolac tromethamine, per 15 mg
J1890 J1930	
J1930	• •
J1940	·
J1950	• •
J1955	
J1960	Levorphanol tartrate, up to 2 mg
J1980	Hyoscyamine sulfate, up to 0.25 mg
J1990	
J2001	Lidocaine HCl for intravenous infusion, 10 mg
J2010	·
J2060	
J2150	1 . 3
J2175	,
J2210	Methylergonovine maleate, up to 0.2 mg
J2248	Micafungin sodium, 1 mg
J2260	
J2270	• • • • • • • • • • • • • • • • • • • •
J2274	Morphine sulfate, preservative-free for epidural or
	intrathecal use, 10 mg
J2278	Ziconotide, 1 mcg
J2310	Naloxone hydrochloride, per 1 mg
J2320	Nandrolone decanoate, up to 50 mg
J2323	Natalizumab, 1 mg
J2353	Octreotide, depot form for intramuscular injection, 1 mg
J2355	Oprelvekin, 5 mg
J2357	Omalizumab, 5 mg
J2358	1 7 0 07 0
J2360	,
J2370	<i>y</i> 1
J2405	, i
J2407	, 6
J2410	, , , , ,
J2425	, 6
J2426	, , ,
J2430	71 0
J2440	, ,
J2460	
J2469	·
J2502	Pasireotide long acting, 1 mg

Version 2017 Page 40 of 59

**Nurse Practitioner Procedure Codes** J2504 Pegademase bovine, 25 IU J2505 Pegfilgrastim, 6 mg J2510 Penicillin G procaine, aqueous, up to 600,000 units J2513 Pentastarch, 10% solution, 100 ml J2515 Pentobarbital sodium, per 50 mg J2540 Penicillin G potassium, up to 600,000 units J2545 Pentamidine isethionate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 300 mg J2550 Promethazine HCl, up to 50 mg J2560 Phenobarbital sodium, up to 120 mg J2590 Oxytocin, up to 10 units J2597 Desmopressin acetate, per 1 mcg Prednisolone acetate, up to 1 ml J2650 J2670 Tolazoline HCl, up to 25 mg J2675 Progesterone, per 50 mg J2680 Fluphenazine decanoate, up to 25 mg J2690 Procainamide HCl, up to 1 gm J2700 Oxacillin sodium, up to 250 mg Neostigmine methylsulfate, up to 0.5 mg J2710 J2720 Protamine sulfate, per 10 mg J2730 Pralidoxime chloride, up to 1 gm Phentolamine mesylate, up to 5 mg J2760 Metoclopramide HCI, up to 10 mg J2765 Ranitidine HCI, 25 mg J2780 J2783 Rasburicase, 0.5 mg J2794 Risperidone, long acting, 0.5 mg J2796 Romiplostim, 10 micrograms J2800 Methocarbamol, up to 10 ml Sargramostim (GM-CSF), 50 mcg J2820 J2860 Siltuximab, 10 mg J2910 Aurothioglucose, up to 50 mg J2916 Sodium ferric gluconate complex in sucrose injection, 12.5 mg J2920 Methylprednisolone sodium succinate, up to 40 mg-J2930 Methylprednisolone sodium succinate, up to 125 mg J2940 Somatrem, 1 mg J2941 Somatropin, 1 mg J2995 Streptokinase, per 250,000 IU Streptomycin, up to 1 gm J3000 J3030 Sumatriptan succinate, 6 mg J3060 Taliglucerace alfa, 10 units

Version 2017 Page 41 of 59

J3070

J3090

J3105

J3121

J3145

Pentazocine, 30 mg

Tedizolid phosphate, 1 mg

Terbutaline sulfate, up to 1 mg

Testosterone, enanthate, 1 mg

Testosterone, undecanoate, 1 mg

J3230 Chlorpromazine HCl, up to 50 mg J3240 Thyrotropin alpha, 0.9 mg. provided in 1.1 mg J3250 Trimethobenzamide HCl, up to 200 mg J3260 Tobramycin sulfate, up to 80 mg J3262 Tocilizumab, 1 mg J3265 Torsemide, 10 mg/ml J3280 Thiethylperazine maleate, up to 10 mg J3285 Treprostinil, 1 mg Triamcinolone acetonide, preservative free, 1 mg J3300 J3301 Triamcinolone acetonide, not otherwise specified, 10 mg J3302 Triamcinolone diacetate, per 5 mg J3303 Triamcinolone hexacetonide, per 5 mg Trimetrexate glucuronate, per 25 mg J3305 J3310 Perphenazine, up to 5 mg Triptorelin pamoate, 3.75 mg J3315 J3320 Spectinomycin dihydrochloride, up to 2 gm J3357 Ustekinumab, 1 mg Diazepam, up to 5 mg J3360 J3364 Urokinase, 5000 IU vial J3370 Vancomycin HCI, 500 mg J3380 Vedolizumab, 1 mg Triflupromazine HCl, up to 20 mg J3400 Hydroxyzine HCI, up to 25 mg J3410 Thiamine HCI, 100 mg J3411 Pyridoxine HCI, 100 mg J3415 J3420 Vitamin B-12 cyanocobalamin, up to 1000 mcg J3430 Phytonadione, (vitamin K), per 1 mg J3470 Hyaluronidase, up to 150 units Magnesium sulfate, per 500 mg J3475 J3480 Potassium chloride, per 2 meg

# J3489 Zoledronic acid, 1 mg J3490 Unclassified drugs

J3520 Edetate disodium, per 150 mg

J3590 Unclassified Biologics

#### MISCELLANEOUS DRUGS AND SOLUTIONS

# Codes followed by an ^ do not require an NDC to be provided when billed.

A4216<sup>^</sup> Sterile water, saline and/or dextrose diluent/flush, 10 ml

A4218<sup>^</sup> Sterile saline or water, metered dose dispenser, 10 ml

J7030 Infusion, normal saline solution (or water), 1000 cc

Infusion, normal saline solution (or water), sterile (500 ml = 1 unit) J7040

J7042 5% dextrose/normal saline (500 ml = 1 unit)

Infusion, normal saline solution (or water), 250 cc J7050

J7060 5% dextrose/water (500 ml = 1 unit)

Version 2017 Page 42 of 59

- J7070 Infusion, D5W, 1000 cc
- J7100 Infusion, Dextran 40, 500 ml
- J7110 Infusion, dextran 75, 500 ml
- J7120 Ringers lactate infusion, up to 1000 cc
- J7121 5% Dextrose in lactated ringers infusion, up to 1000 cc
- J7131 Hypertonic saline solution, 1 ml
- J7297 Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 3 year duration
- J7298 Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 5 year duration
- J7300 Intrauterine copper contraceptive
- J7301 Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg
- J7303 Contraceptive supply, hormone containing vaginal ring, each
- J7304 Contraceptive supply, hormone containing patch, each
- J7306 Levonorgestrel (contraceptive) implant system, including implants and supplies
- J7307 Etonogestrel (contraceptive) implant system, including implant and supplies
- J7308 Aminolevulinic acid HCl for topical administration, 20%, single unit dosage form (354 mg)
- J7321<sup>^</sup> Hyaluronan or derivative, Hyalgan or Supartz, for intra-articular injection, per dose
- J7323<sup>^</sup> Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
- J7324<sup>^</sup> Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
- J7325<sup>^</sup> Hyaluronan or derivative, Synvisc or Synvisc-One, intra-articular
- J7326 Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
- J7336 Capsaicin 8% patch, per square centimeter
- J7501 Azathioprine, parenteral (eg Imuran), 100 mg
- J7504 Lymphocyte immune globulin, antithymocyte globulin equine, parenteral, 250 mg
- J7606 Formoterol fumarate, inhalation solution, non-compounded, administered through DME, unit dose form, 20 mcg
- J7611 Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 1mg
- J7612 Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, 0.5 mg
- J7613 Albuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose, 1 mg
- J7614 Levalbuterol, inhalation solution, FDA-approved final product, non-compounded, administered through DME. Unit dose. 0.5 mg
- J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, FDA-approved final product, non-compounded, administered through DME
- J7627 Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg
- J7628 Bitolterol mesylate, inhalation solution, compounded product, administered through DME, concentrated form, per mg
- J7631 Cromolyn sodium, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 mg
- J7640 Formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 mcg
- J7644 Ipratropium bromide, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg

Version 2017 Page 43 of 59

- J7648 Isoetharine HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
- J7649 Isoetharine HCl, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per mg
- J7658 Isoproterenol HCI, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per mg
- J7668 Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, concentrated form, per 10 mg
- J7669 Metaproterenol sulfate, inhalation solution, FDA-approved final product, non-compounded, administered through DME, unit dose form, per 10 mg
- J7674 Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg
- J7682 Tobramycin, inhalation solution, FDA-approved final product, non-compounded, unit dose form, administered through DME, 300 mg
- J7999 Compounded drug, not otherwise classified
- J8501 Aprepitant, oral, 5 mg
- J8540 Dexamethasone, oral, 0.25 mg
- J8650 Nabilone, oral, 1 mg
- J9226 Histrelin implant (Supprelin LA), 50 mg

# HYDRATION, THERAPEUTIC, PROPHYLACTIC, DIAGNOSTIC INJECTIONS and INFUSIONS, and CHEMOTHERAPY and OTHER HIGHLY COMPLEX DRUG or HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

Physician work related to hydration, injection, and infusion services predominantly involves affirmation of treatment plan and direct supervision of staff.

If a significant separately identifiable Evaluation and Management service is performed, the appropriate E/M service code should be reported using modifier '25' in addition to 96360-96549. For same day E/M service a different diagnosis is not required.

If performed to facilitate the infusion or injection, the following services are included and are not reported separately:

- a. Use of local anesthesia
- b. IV start
- c. Access to indwelling IV, subcutaneous catheter or port
- d. Flush at conclusion of infusion
- e. Standard tubing, syringes, and supplies

When multiple drugs are administered, report the service(s) and the specific materials or drugs for each.

When administering multiple infusions, injections or combinations, only one "initial" service code should be reported, unless protocol requires that two separate IV sites must be used. If an injection or infusion is of a subsequent or concurrent nature, even if it is the first such service within that group of services, then a subsequent or concurrent code from the appropriate section should be reported (eg,

Version 2017 Page 44 of 59

the first IV push given subsequent to an initial one-hour infusion is reported using a subsequent IV push code). When these codes are reported by the physician, the "initial" code that best describes the key or primary reason for the encounter should always be reported irrespective of the order in which the infusions or injections occur. When reporting codes for which infusion time is a factor, use the actual time over which the infusion is administered. Intravenous or intra-arterial push is defined as: (a) an injection in which the health care professional who administers the substance/drug is continuously present to administer the injection and observe the patient, or (b) an infusion of 15 minutes or less.

## **HYDRATION**

Codes 96360-96361 are intended to report a hydration IV infusion to consist of a pre-packaged fluid and electrolytes (eg, normal saline, D5-1/2 normal saline+30mEq KCl/liter), but are not used to report infusion of drugs or other substances. Hydration IV infusions typically require direct physician supervision for purposes of consent, safety oversight, or intraservice supervision of staff. Typically such infusions require little special handling to prepare or dispose of, and staff that administer these do not typically require advanced practice training. After initial set-up, infusion typically entails little patient risk and thus little monitoring. These codes are not intended to be reported by the physician in the facility setting.

96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour

(Do not report 96360 if performed as a concurrent infusion service)

(Do not report intravenous infusion for hydration of 30 minutes or less)

96361 each additional hour

(List separately in addition to primary procedure)

(Use 96361 in conjunction with 96360)

(Report 96361 for hydration infusion intervals of greater than 30 minutes beyond 1 hour

increments)

(Report 96361 to identify hydration if provided as a secondary or subsequent service after a different initial service [96360, 96365, 96409, 96413] is administered through the

same IV access)

# THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC INJECTIONS AND INFUSIONS (EXCLUDES CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION)

A therapeutic, prophylactic or diagnosis IV infusion or injection (other than hydration) is for the administration of substances/drugs. When fluids are used to administer the drug(s), the administration of the fluid is considered incidental hydration and is not separately reportable. These services typically require direct physician supervision for any or all purposes of patient assessment, provision of consent, safety oversight, and intra-service supervision of staff. Typically, such infusions require special consideration to prepare, dose or dispose of, require practice training and competency for staff who administer the infusions, and require periodic patient assessment with vital sign monitoring during the infusion. These codes are not intended to be reported by the physician in the facility setting.

(Do not report 96365-96371 with codes for which IV push or infusion is an inherent part of the procedure [eg, administration of contrast material for a diagnostic imaging study])

Version 2017 Page 45 of 59

96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drugs); up to 1 hour

96366 each additional hour

(List separately in addition to primary procedure) (Report 96366 in conjunction with 96365, 96367)

(Report 96366 for additional hour[s] of sequential infusion)

(Report 96366 for infusion intervals of greater than 30 minutes beyond 1 hour

increments)

additional sequential infusion of a new drug/substance, up to 1 hour

(List separately in addition to primary procedure)

(Report 96367 in conjunction with 96365, 96409, 96413 to identify the infusion of a new drug/substance provided as a secondary or subsequent service after a different initial service is administered through the same IV access.

(Report 96367 only once per sequential infusion of same infusate mix)

96368 concurrent infusion

(List separately in addition to primary procedure)

(Report 96368 only once per encounter)

(Report 96368 in conjunction with 96365, 96366, 96413, 96415, 96416)

96369 Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)

96370 each additional hour

(List separately in addition to primary procedure)

(Use 96370 in conjunction with 96369)

(Use 96370 for infusion intervals of greater than 30 minutes beyond 1 hour increments)

additional pump set-up with establishment of new subcutaneous infusion site(s)

(List separately in addition to primary procedure)

(Use 96371 in conjunction with 96369)

(Use 96369, 96371 only once per encounter)

96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular (Bill on one claim line for multiple injections)

# CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

Procedures 96405-96549 are independent of the patient's office visit. Either may occur independently from the other on any given day, or they may occur sequentially on the same day. Intravenous chemotherapy injections are administered by a physician, a nurse practitioner or by a qualified assistant under supervision of the physician or nurse practitioner. Preparation of chemotherapy agent(s) is included in the service for administration of the agent.

# INJECTION AND INTRAVENOUS INFUSION CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

96405 Chemotherapy administration; intralesional; up to and including 7 lesions

96406 intralesional, more than 7 lesions

96409 intravenous, push technique, single or initial substance/drug

Version 2017 Page 46 of 59

96413 Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

(Report 96361 to identify hydration if administered as a secondary or subsequent service in association with 96413 through the same IV assess)

(Report 96366, 96367, to identify therapeutic, prophylactic, or diagnostic drug infusion or injection, if administered as a secondary or subsequent service in association with 96413 through the same IV access)

96415 each additional hour

(List separately in addition to primary procedure)

(Use 96415 in conjunction with 96413)

(Report 96415 for infusion intervals of greater than 30 minutes beyond 1-hour

increments)

96416 initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a

portable or implantable pump

# INTRA-ARTERIAL CHEMOTHERAPY AND OTHER HIGHLY COMPLEX DRUG OR HIGHLY COMPLEX BIOLOGIC AGENT ADMINISTRATION

COMPLEX BIOLOGIC AGENT ADMINISTRATION		
96420	Chemotherapy administration, intra-arterial; push technique	
96422	infusion technique, up to 1 hour	

96423 infusion technique, each additional hour

(List separately in addition to primary procedure) (Use 96423 in conjunction with code 96422)

(Report 96423 for infusion intervals of greater than 30 minutes beyond 1-hour

increments)

96425 infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use

of a portable or implantable pump

# OTHER INJECTION AND INFUSION SERVICES

- 96440 Chemotherapy administration into pleural cavity, requiring and including thoracentesis
- 96446 Chemotherapy administration into the peritoneal cavity via indwelling port or catheter
- 96450 Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture
- 96521 Refilling and maintenance of portable pump
- 96522 Refilling and maintenance of implantable pump or reservoir for drug delivery, systemic, (eg, intravenous, intra-arterial)
- 96542 Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reservoir, single or multiple agents
- 96549 Unlisted chemotherapy procedure
- J9999 Not otherwise classified, antineoplastic drugs

# **CHEMOTHERAPY DRUGS**

(Maximum fee is for chemotherapy drug only and does not include the administration procedures as listed above)

Version 2017 Page 47 of 59

**NOTE**: The maximum fees for these drugs are adjusted periodically by the State to reflect the estimated acquisition cost. Insert actual acquisition cost per dose in amount charged field on claim form. For codes listed BR/Report required, also attach itemized invoice to claim form.

Reimbursement for drugs furnished by practitioners to their patients is based on the acquisition cost to the practitioner of the drug dose administered to the patient. For all drugs furnished in this fashion it is expected that the practitioner will maintain auditable records of the actual itemized invoice cost of the drug, including the numbers of doses of the drug represented on the invoice. New York State Medicaid does not intend to pay more than the acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless of whether an invoice must be submitted to Medicaid for payment, the practitioner is expected to limit his or her Medicaid claim amount to the actual invoice cost of the drug dosage administered.

# Codes followed by an ^ do not require an NDC to be provided when billed.

- J9000 Doxorubicin HCL (Adriamycin), 10 mg
- J9015 Aldesleukin, per single use vial
- J9017 Arsenic trioxide, 1 mg (Trisenox)
- J9020 Asparaginase (Elspar) 10,000 units
- J9025 Azacitidine, 1 mg
- J9027 Clofarabine, 1 mg
- J9031 BCG (intravesical) per instillation
- J9032 Belinostat, 10 mg
- J9033 Bendamustine HCL (Treanda), 1 mg
- J9034 Bendamustine HCL (Bendeka), 1 mg
- J9035 Bevacizumab, 10 mg
- J9039 Blinatumomab, 1 microgram
- J9040 Bleomycin sulfate (Blenoxane), 15 units
- J9041 Bortezomib, 0.1 mg
- J9043 Carboplatin, 50 mg
- J9045 Carboplatin, 50 mg
- J9047 Carfilzomib, 1 mg
- J9050 Carmustine, 100 mg
- J9055 Cetuximab, 10 mg
- J9060 Cisplatin, powder or solution, 10 mg
- J9065 Cladribine, per 1 mg
- J9070 Cyclophosphamide, 100 mg
- J9098 Cytarabine liposome, 10 mg
- J9100 Cytarabine (Cytosar-U), 100 mg
- J9120 Dactinomycin (Cosmegen), 0.5 mg
- J9130 Dacarbazine, 100 mg
- J9145 Daratumumab, 10 mg
- J9150 Daunorubicin HCL, 10 mg
- J9151 Daunorubicin citrate, liposomal formulation, 10 mg
- J9155 Degarelix, 1 mg
- J9160 Denileukin diftitox, 300 mcg
- J9165 Diethylstilbestrol diphosphate, 250 mg

Version 2017 Page 48 of 59

#### re Codes

	Nurse Practitioner Procedure Codes
J9171	Docetaxel, 1 mg
J9176	Elotuzumab, 1 mg
J9178	Epirubicin HCL, 2 mg
J9170 J9179	Eribulin mesylate, 0.1mg
J9179 J9181	Etoposide, 10 mg
J9185	Fludarabine phosphate, 50 mg
J9190	Fluorouracil, 500 mg
J9200	Floxuridine (FUDR), 500 mg
J9200 J9201	Gemcitabine HCI, 200 mg
J9201 J9202	•
	Goserelin acetate implant per 3.6 mg
J9205	Irinotecan liposome, 1 mg
J9206	Irinotecan, 20 mg
J9207	Ixabepilone, 1 mg
J9208	Ifosfamide, 1 gm
J9209	Mesna, 200 mg
J9211	Idarubicin HCI, 5 mg
J9212 J9213	Interferon Alfacon-1, Recombinant, 1 mcg
	Interferon, Alfa-2A, Recombinant, 3 million units
J9214	Interferon, Alfa-2B, Recombinant, 1 million units
J9215	Interferon, Alfa-N3, (Human Leukocyte Derived), 250,000 IU
J9216	Interferon, Gamma 1-B, 3 million units
J9217	Leuprolide acetate (for Depot Suspension), 7.5 mg
J9218	Leuprolide acetate, per 1 mg
	Leuprolide acetate implant, 65 mg
J9225	Histrelin implant (Vantas), 50 mg
J9228 J9230	Ipilimumab, 1mg Mechlorethamine HCl (nitrogen mustard), 10 mg
J9230 J9245	Melphalan HCl, 50 mg
J9250	Methotrexate sodium, 5 mg
J9260	Methotrexate sodium, 50 mg
J9261	Nelarabine, 50 mg
J9262	Omacetaxine mepesuccinate, 0.01 mg
J9263	Oxaliplatin (Eloxatin), 0.5 mg
J9264	Paclitaxel protein-bound particles, 1 mg
J9266	Pegaspargase, per single dose vial
J9267	Paclitaxel, 1 mg
J9268	Pentostatin, per 10 mg
J9270	Plicamycin, 2.5 mg
J9271	Pembrolizumab, 1 mg
J9280	Mitomycin, 5 mg
J9293	Mitoxantrone HCl, per 5 mg
J9295	Necitumumab, 1 mg
J9299	Nivolumab, 1 mg

J9300 Gemtuzumab ozogamicin, 5 mg Obinutuzumab, 10 mg

J9302 Ofatumumab, 10 mg J9303 Panitumumab, 10 mg

J9301

Version 2017 Page 49 of 59

J9305	Pemetrexed, 10 mg
J9306	Pertuzumab, 1 mg
J9307	Pralatrexate, 1 mg
J9308	Ramucirumab, 5 mg
J9310	Rituximab, 100 mg
J9315	Romidepsin, 1 mg
J9320	Streptozocin, 1 gm
J9325	Talimogene laherparepvec, per 1 million plaque forming units
J9330	Temsirolimus, 1 mg
J9340	Thiotepa, 15 mg
J9351	Topotecan, 0.1 mg
J9352	Trabectedin, 0.1 mg
J9354	Ado-trastuzumab emtansine, 1 mg
J9355	Trastuzumab, 10 mg
J9357	Valrubicin, intravesical, 200 mg
J9360	Vinblastine sulfate, 1 mg
J9370	Vincristine sulfate, 1 mg
J9371	Vincristine sulfate liposome, 1 mg
J9390	Vinorelbine Tartrate, 10 mg
J9395	Fulvestrant (Faslodex), 25 mg
J9400	Ziv-aflibercept, 1 mg
J9600	Porfimer sodium, 75 mg
J9999	Not Otherwise Classified, Antineoplastic Drugs
Q0174	Thiethylperazine Maleate, 10 mg, oral
Q0177	Hydroxyzine Pamoate, 25 mg, oral
Q2017	Teniposide, 50 mg
Q2050	Doxorubicin HCL liposomal, NOS, 10 mg

# **PSYCHIATRY**

Note: To bill for the following codes, you must be certified by the NYS Education Department as a Nurse Practitioner in Psychiatry (Profession Code 040)

	,
90785	Interactive complexity (List separately in addition to primary procedure)
90791	Psychiatric diagnostic evaluation
90792	Psychiatric diagnostic evaluation with medical services

# **PSYCHOTHERAPY**

<u> </u>	PSTUNUTNERAPT		
90832	Psychotherapy, 30 minutes with patient		
90833	Psychotherapy, 30 minutes with patient when performed with an evaluation and management service		
	(List separately in addition to the code for primary procedure)		
90834	Psychotherapy, 45 minutes with patient		
90836	Psychotherapy, 45 minutes with patient when performed with an evaluation and management service		
	(List separately in addition to the code for primary procedure)		

90837 Psychotherapy, 60 minutes, with patient

Version 2017 Page 50 of 59

90838 Psychotherapy, 60 minutes with patient when performed with an evaluation and management service

(List separately in addition to the code for primary procedure)

# OTHER PSYCHOTHERAPY

- 90846 Family psychotherapy (without the patient present), 50 minutes
- 90847 Family psychotherapy (conjoint psychotherapy) (with patient present), 50 minutes
- 90849 Multiple-family group psychotherapy
- 90853 Group psychotherapy (other than of a multiple-family group)

# OTHER PSYCHIATRIC SERVICES OR PROCEDURES

90863 Pharmacologic management, including prescription and review of medication, when performed with psychotherapy services (List separately in addition to primary procedure)

# SPECIAL OPHTHALMOLOGICAL SERVICES

- 92071 Fitting of contact lens for treatment of ocular surface disease (Do not report 92071 in conjunction with 92072)
- 92072 Fitting of contact lens for management of keratoconus, initial fitting (Do not report 92072 in conjunction with 92071)

# SPECIAL OTORHINOLARYNGOLOGIC SERVICES

Diagnostic or treatment procedures that are reported as evaluation and management services (eg, otoscopy, anterior rhinoscopy, tuning fork test, removal of non-impacted cerumen) are not reported separately.

Special otorhinolaryngologic services are those diagnostic and treatment services not included in an Evaluation and Management service. These services are reported separately, using codes 92502-92700.

# **VESTIBULAR FUNCTION TESTS, WITH RECORDING (eg, ENG)**

- 92537 Caloric vestibular test with recording, bilateral; bithermal (ie, one warm and one cool irrigation in each ear for a total of four irrigations)
- 92538 monothermal (ie, one irrigation in each ear for a total of two irrigations)
- 92540 Basic vestibular evaluation, includes spontaneous nystagmus test with eccentric gaze fixation nystagmus, with recording, positional nystagmus test, minimum of 4 positions, with recording, optokinetic nystagmus test, bidirectional foveal and peripheral stimulation, with recording, and oscillating tracking test, with recording
- 92541 Spontaneous nystagmus test, including gaze and fixation nystagmus, with recording

Version 2017 Page 51 of 59

- 92542 Positional nystagmus test, minimum of 4 positions, with recording
- 92544 Optokinetic nystagmus test, bidirectional, foveal or peripheral stimulation, with recording
- 92545 Oscillating tracking test, with recording
- 92546 Sinusoidal vertical axis rotational testing

## **AUDIOLOGIC FUNCTION TESTS**

The audiometric tests listed below require the use of calibrated electronic equipment, recording of results and a report with interpretation. Hearing tests (such as whispered voice, tuning fork) that are otorhinolaryngologic Evaluation and Management services are not reported separately. All services include testing of both ears.

- 92550 Tympanometry and reflex threshold measurements
- 92551 Screening test, pure tone, air only
- 92552 Pure tone audiometry (threshold); air only
- 92553 air and bone
- 92555 Speech audiometry threshold
- 92556 with speech recognition
- 92557 Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)
- 92563 Tone decay test
- 92565 Stenger test, pure tone
- 92567 Tympanometry (impedance testing)
- 92568 Acoustic reflex testing; threshold
- 92570 Acoustic immittance testing, includes tympanometry (impedance testing), acoustic reflex threshold testing, and acoustic reflex decay testing
- 92571 Filtered speech test
- 92585 Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; comprehensive
- 92586 limited
- 92587 Distortion product evoked otoacoustic emissions; limited evaluation (to confirm the presence or absence of hearing disorder, 3-6 frequencies) or transient evoked otoacoustic emissions, with interpretation and report

# **CARDIOVASCULAR**

# **CARDIOGRAPHY**

- 93000 Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report
- 93010 interpretation and report only

# **PULMONARY**

Codes 94010-94799 include laboratory procedure(s) and interpretation of test results.

- 94010 Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation
- 94011 Measurement of spirometric forced expiratory flows in an infant or child through 2 years of age

Version 2017 Page 52 of 59

- 94012 Measurement of spirometric forced expiratory flows, before and after bronchodilator, in an infant or child through 2 years of age
- 94013 Measurement of lung volumes (ie, functional residual capacity [FRC], forced vital capacity [FVC], and expiratory reserve volume [ERV] in an infant or child through 2 years of age
- 94014 Patient-initiated spirometric recording per 30-day period of time; includes reinforced education, transmission of spirometric tracing, data capture, analysis of transmitted data, periodic recalibration and physician review and interpretation
- 94016 physician review and interpretation only
- 94060 Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration
- 94200 Maximum breathing capacity, maximal voluntary ventilation
- 94644 Continuous inhalation treatment with aerosol medication for acute airway obstruction; first hour
- each additional hour (List separately in addition to primary procedure)
- 94664 Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device (94664 can be reported one time only per day of service)

# ALLERGY AND CLINICAL IMMUNOLOGY

Immunotherapy (desensitization, hyposensitization) is the parenteral administration of allergenic extracts as antigens at periodic intervals, usually on an increasing dosage scale to a dosage which is maintained as maintenance therapy. Indications for immunotherapy are determined by appropriate diagnostic procedures coordinated with clinical judgment and knowledge of the natural history of allergic diseases.

**SENSITIVITY TESTING** (Maximum fees include reading of test)

86580 Skin test; tuberculosis, intradermal

#### ALLERGEN IMMUNOTHERAPY

- 95115 Professional services for allergen immunotherapy not including provision of allergenic extracts; single injection
- 95117 2 or more injections

# **MISCELLANEOUS SERVICES**

- 93797 Physician services for outpatient cardiac rehabilitation; without continuous ECG monitoring (per session)
- 93798 with continuous ECG monitoring (per session)
- 95990 Refilling and maintenance of implantable pump or reservoir for drug delivery, spinal (intrathecal, epidural) or brain (intraventricular), includes electronic analysis of pump, when performed
- 96040 Medical genetics and genetic counseling services, each 30 minutes face-to-face with patient/family
- 97542# Wheelchair management (eg, assessment, fitting, training), each 15 minutes (up to a maximum of 2 hours)

Version 2017 Page 53 of 59

- 98960 Education and training for patient self-management by a qualified, non physician health care professional using a standardized curriculum, face-to-face with the patient (could include caregiver/family) each 30 minutes; individual patient
- 98961 2-4 patients
- 98962 5-8 patients
- 99050 Services provided in the office at times other than regularly scheduled office hours, or days when the office is normally closed (eg, holidays, Saturday or Sunday), in addition to basic service
- 99051 Service(s) provided in the office during regularly scheduled evening, weekend, or holiday office hours, in addition to basic service
- 99070 Supplies and materials (except spectacles), provided by the physician over and above those usually included with the office visit or other services rendered (List drugs, trays, supplies, or materials provided)
- 99170 Anogenital examination, magnified in childhood for suspected trauma, including image recording when performed
- 99188 Application of topical fluoride varnish by a physician or other qualified health care professional
- G0108 Diabetes outpatient self-management training services, individual, per 30 minutes
- G0109 group session (2 or more), per 30 minutes
- G0372 Physician service required to establish and document the need for a power mobility device
- G8431 Screening for clinical depression is documented as being positive and a follow-up plan is documented
- G8510 Screening for clinical depression is documented as being negative, a follow-up plan Is not required
- H0049 Alcohol and/or drug screening
- H0050 Alcohol and/or drug services, brief intervention, per 15 minutes
- S9445 Patient education, not otherwise classified, non-physician provider, individual, per session. (The initial lactation counseling session should be a minimum of 45 minutes. Follow up session(s) should be a minimum of 30 minutes.)
- S9446 Patient education, not otherwise classified, non-physician provider, individual, per session. (The initial lactation counseling session should be a minimum of 45 minutes. Follow up session(s) should be a minimum of 30 minutes.)
  - NYS Medicaid will provide reimbursement for separate and distinct breastfeeding services provided by International Board Certified Lactation Consultants (IBCLCs) credentialed by the IBCLCE. For additional information see:
  - http://www.health.ny.gov/health\_care/medicaid/program/update/2013/2013-03.htm#fee
- T1013 Sign language or oral interpretive services, per 15 minutes

# **SURGERY SECTION**

# **GENERAL INFORMATION AND RULES**

1. **FEES**: Fees for office, home and hospital visits and other medical services are listed in the section entitled MEDICINE.

Version 2017 Page 54 of 59

- 2. **FOLLOW UP (F/U) DAYS**: Listed dollar values for all surgical procedures include the surgery and the follow-up care for the period indicated in days in the column headed "F/U Days". Necessary follow-up care beyond this listed period is to be added on a fee-for-service basis. (See modifier 24)
- 3. **BY REPORT**: When the value of a procedure is indicated as "By Report" (BR), an Operative Report must be submitted with the MMIS claim form for a payment determination to be made. The Operative Report must include the following information:
  - a. Diagnosis (post-operative)
  - b. Size, location and number of lesion(s) or procedure(s) where appropriate
  - c. Major surgical procedure and supplementary procedure(s)
  - d. Whenever possible, list the nearest similar procedure by number according to these studies
  - e. Estimated follow-up period
  - f. Operative time

Failure to submit an Operative Report when billing for a "By Report" procedure will cause your claim to be <u>denied</u> by MMIS.

4. **ADDITIONAL SERVICES**: Complications or other circumstances requiring additional and unusual services concurrent with the procedure(s) or during the listed period of normal follow-up care may warrant additional charges on a fee-for-service basis. (See modifiers -24, -25, -79). When an additional surgical procedure(s) is carried out within the listed period of follow-up care for a previous surgery, the follow-up periods will continue concurrently to their normal terminations.

#### 5. MULTIPLE SURGICAL PROCEDURES:

- a. When multiple or bilateral surgical procedures, which add significant time or complexity to patient care, are performed at the same operative session, the total dollar value shall be the value of the major procedure plus 50% of the value of the lesser procedure(s) unless otherwise specified.
- b. When an incidental procedure (eg, incidental appendectomy, lysis of adhesions, excision of previous scar, puncture of ovarian cyst) is performed through the same incision, the fee will be that of the major procedure only.
- 6. **ASSIST AT SURGERY**: When a physician requests a nurse practitioner or a physician's assistant to participate in the management of a specific surgical procedure in lieu of another physician, by prior agreement, the total value may be apportioned in relation to the responsibility and work done, provided the patient is made aware of the fee distribution according to medical ethics. The value may be increased by 20 percent under these circumstances. The claim for these services will be submitted by the physician using the appropriate modifier.

## INTEGUMENTARY SYSTEM

SKIN, SUBCUTANEOUS AND AREOLAR TISSUES

#### **INCISION AND DRAINAGE**

Version 2017 Page 55 of 59

10060	Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or
	subcutaneous abscess, cyst, furuncle, or paronychia); simple or single
10061	complicated or multiple
10120	Incision and removal of foreign body, subcutaneous tissues; simple
10140	Incision and drainage of hematoma, seroma or fluid collection
10160	Puncture aspiration of abscess, hematoma, bulla, or cyst

#### **BIOPSY**

- 11100 Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion
- 11101 each separate/additional lesion

(List separately in addition to primary procedure)

(Use 11101 in conjunction with 11100)

#### **REMOVAL OF SKIN TAGS**

Excision (including simple closure) of benign lesions of skin or subcutaneous tissues (eg, neoplasm, cicatricial, fibrous, inflammatory, congenital, cystic lesions), includes local anesthesia. See appropriate size and area below.

- 11200 Removal of skin tags, multiple fibrocutaneous tags, any area; up to and including 15 lesions
- 11400 Excision, benign lesion including margins, except skin tag (unless listed elsewhere), trunk, arms or legs; excised diameter 0.5 cm or less

#### INTRODUCTION

- 11976 Removal, implantable contraceptive capsules
- 11981 Insertion, non-biodegradable drug delivery implant
- 11982 Removal, non-biodegradable drug delivery implant
- 11983 Removal with reinsertion, non-biodegradable drug delivery implant

#### **REPAIR**

Simple repair is used when the wound is superficial; eg, involving primarily skin and/or subcutaneous tissues without significant involvement of deeper structures, and requires simple one layer closure. FOR CLOSURE WITH ADHESIVE STRIPS, LIST APPROPRIATE EVALUATION AND MANAGEMENT SERVICE ONLY.

Instructions for listing services at time of wound repair.

- 1. The repaired wound(s) should be measured and recorded in centimeters, whether curved, angular or stellate.
- 2. When multiple wounds are repaired, add together the lengths of those in the same classification (see above) and report as a single item.

Simple ligation of vessels in an open wound is considered as part of any wound closure. Simple exploration of nerves, blood vessels or tendons exposed in an open wound is also considered part of the essential treatment of the wound and is not a separate procedure unless appreciable dissection is required.

Version 2017 Page 56 of 59

#### **REPAIR-SIMPLE**

12001	Simple repair of superficial wounds of scalp, neck, axillae, external genitalia, trunk and/or
	extremities (including hands and feet); 2.5 cm or less
12002	2.6 cm to 7.5 cm
12004	7.6 cm to 12.5 cm
12005	12.6 cm to 20.0 cm
12011	Simple repair of superficial wounds of face, ears, eyelids, nose, lips and/or mucous
	membranes; 2.5 cm or less
12013	2.6 cm to 5.0 cm
12014	5.1 cm to 7.5 cm
12015	7.6 cm to 12.5 cm
12016	12.6 cm to 20.0 cm

#### **BURNS, LOCAL TREATMENT**

Procedures 16000 and 16020 refer to local treatment of burned surface only.

List percentage of body surface involved and depth of burn.

For necessary related medical services (eg, hospital visits) in management of burned patients, see appropriate services in **Medicine** section.

- 16000 Initial treatment, first degree burn, when no more than local treatment is required
- 16020 Dressings and/or debridement of partial-thickness burns, initial or subsequent; small (less than 5% total body surface area)

#### **DESTRUCTION**

- 17000 Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses); first lesion
- 17003 second through 14 lesions, each

(List separately in addition to code for first lesion)

(Use 17003 in conjunction with 17000)

- 17004 Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), premalignant lesions (eg, actinic keratoses), 15 or more lesions (Do not report 17004 in conjunction with17000 -17003)
- 17106 Destruction of cutaneous vascular proliferative lesions (eg, laser technique); less than 10 sq cm
- 17107 10.0 to 50.0 sq cm
- 17108 over 50.0 sq cm
- 17110 Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions
- 17111 15 or more lesions
- 17250 Chemical cauterization of granulation tissue (proud flesh, sinus or fistula)

# **DIGESTIVE SYSTEM**

**STOMACH** 

Version 2017 Page 57 of 59

43760 Change of gastrostomy tube, percutaneous, without imaging or endoscopic guidance

## **FEMALE GENITAL SYSTEM**

#### **VULVA AND INTROITUS**

## **DESTRUCTION**

56501 Destruction of lesion(s), vulva; simple (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery)

# <u>REPAIR</u>

56820 Colposcopy of the vulva;

# **VAGINA**

# INTRODUCTION

57150 Irrigation of vagina and/or application of medicament for treatment of bacterial, parasitic, or fungoid disease

## **ENDOSCOPY**

57420 Colposcopy of the entire vagina, with cervix if present

57452 Colposcopy of the cervix including upper/adjacent vagina;

# **CORPUS UTERI**

#### INTRODUCTION

(For materials supplied by a practitioner, see General Information #7)

58300 Insertion of intrauterine device (IUD)

58301 Removal of intrauterine device (IUD)

# **MATERNITY CARE**

Antepartum care includes usual prenatal services (initial and subsequent history, physical examinations, recording of weight, blood pressure, fetal heart tones, routine chemical urinalysis, maternity counseling).

Postpartum care includes hospital and office visits following vaginal or cesarean section delivery.

For medical complications of pregnancy (toxemia, cardiac problems, neurological problems or other problems requiring additional or unusual services or requiring hospitalization), see services in **MEDICINE** section.

## **ANTEPARTUM AND POSTPARTUM CARE**

Reimbursement amounts for the Medicaid Obstetrical and Maternal Services Program (MOMS) are noted in the **Enhanced Program Fee Schedule**. For information on the MOMS Program see Policy Guidelines.

Version 2017 Page 58 of 59

59412 External cephalic version, with or without tocolysis

59425 Antepartum care only; 4-6 visits

59426 7 or more visits

(For 6 or less antepartum encounters, see code 59425)

**Note**: Antepartum services will no longer require prorated charges. This applies to all prenatal care providers, including those enrolled in the MOMS program. Providers should bill one unit of the appropriate antepartum code after all antepartum care has been rendered using the last antepartum visit as the date of service. Only one antepartum care code will be reimbursed per pregnancy.

59430 Postpartum care only (separate procedure)

(When inpatient postpartum care is provided, see appropriate Hospital Evaluation and Management code(s).)

# **NERVOUS SYSTEM**

#### **RESERVOIR/PUMP IMPLANTATION**

62367 Electronic analysis of programmable, implanted pump for intrathecal or epidural drug infusion (includes evaluation of reservoir status, alarm status, drug prescription status); without reprogramming or refilling

62368 with reprogramming

62369 with reprogramming and refill

# **AUDITORY SYSTEM**

69200 Removal foreign body from external auditory canal; without general anesthesia

69210 Removal impacted cerumen requiring instrumentation (report one unit for unilateral **OR** bilateral procedure.)

Version 2017 Page 59 of 59